[COMPANY_001] Research and Development  
CFZ533 
Clinical Trial Protocol CCFZ533B2201E1 / [STUDY_ID_REMOVED]
A TWINSS extension trial to evaluate the safety and 
tolerability of CFZ533 (iscalimab) at two dose levels 
administered subcutaneously in patients with Sjögren’s 
Syndrome 
Document type:  Amended Protocol Version  
EUDRACT number:  2020 -001942 -20 
Version number:  v01 (Clean ) 
Clinical Trial Phase:  IIb 
Release date:  17-Feb-2021
Property of [COMPANY_001]  
Confidential  
May not be used, divulged, published, or otherwise disclosed  
without the consent of [COMPANY_001]  
Clinical Trial Protocol Template Version 3.0 dated 31 -Jan-2020  
[COMPANY_001]  Confidential  Page 2 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 Table of contents  
Table of contents ................................................................................................................. [ADDRESS_1014008] of abbreviations  ............................................................................................................ 7 
Glossary of terms  ............................................................................................................... 11 
Amendment 1 (17- Feb-2021) ................................................................................................... 13 
Protocol summary  .............................................................................................................. 15 
1 Introduction ....................................................................................................................... 17 
1.1 Background ............................................................................................................ 17 
1.2 Purpose .................................................................................................................. 17 
2 Objectives and endpoints ................................................................................................... 18 
2.1 Primary estimands  ................................................................................................. 19 
2.2 Secondary estimands ............................................................................................. 19 
3 Study design ...................................................................................................................... 19 
4 Rationale ............................................................................................................................ 21 
4.1 Rationale for study design ..................................................................................... 21 
4.1.1 Rationale for choice of background therapy ......................................... 22 
4.2 Rationale for dose/regimen and duration of treatment .......................................... 22 
4.3 Rationale for choice of control drugs (comparator/placebo) or combination drugs ...................................................................................................................... 23
 
4.4 Purpose and timing of interim analyses/design adaptations .................................. 24 
4.5 Risks and benefits .................................................................................................. 24 
4.6 Rationale for Public Health Emergency mitigation procedures  ............................ 26 
5 Study Population ............................................................................................................... 26 
5.1 Inclusion criteria  .................................................................................................... 26 
5.2 Exclusion criteria  ................................................................................................... 26 
6 Treatment  ........................................................................................................................... 28 
6.1 Study treatment ...................................................................................................... 28 
6.1.1 Investigational and control drugs .......................................................... 28 
6.1.2 Additional study treatments .................................................................. 29 
6.1.3 Treatment arms/group  ........................................................................... 29 
6.1.4 Treatment duration  ................................................................................ 31 
6.2 Other treatment(s)  .................................................................................................. 31 
6.2.1 Concomitant therapy  ............................................................................. 32 
6.2.2 Prohibited medication  ........................................................................... 32 
[COMPANY_001]  Confidential  Page 3 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 6.2.3 Rescue medication  ................................................................................ 33 
6.3 Participant numbering, treatment assignment, randomization  .............................. 34 
6.3.1 Participant numbering  ........................................................................... 34 
6.3.2 Treatment assignment, randomization  .................................................. 34 
6.4 Treatment blinding  ................................................................................................ 35 
6.5 Dose escalation and dose modification .................................................................. 36 
6.5.1 Dose modifications ................................................................................ 36 
6.5.2 Dose interruptions ................................................................................. 36 
6.5.3 Follow-up for toxicities ......................................................................... 37 
6.6 Additional treatment guidance ............................................................................... 37 
6.6.1 Treatment compliance  ........................................................................... 37 
6.6.2 Emergency breaking of assigned treatment code  .................................. 37 
6.7 Preparation and dispensation  ................................................................................. 38 
6.7.1 Handling of study treatment and additional treatment .......................... 38 
6.7.2 Instruction for prescribing and taking study treatment ......................... 40 
7 Informed consent procedures ............................................................................................ 41 
8 Visit schedule and assessments  ......................................................................................... 43 
8.1 Screening  ............................................................................................................... 49 
8.1.1 Information to be collected on screening failures ................................. 49 
8.2 Participant demographics/other baseline characteristics  ....................................... 49 
  49 
  49 
  49 
  50 
  50 
  50 
  50 
8.4 Safety  ..................................................................................................................... 50 
8.4.1 Laboratory evaluations  .......................................................................... 51 
8.4.2 Electrocardiogram (ECG) ..................................................................... 52 
8.4.3 Pregnancy and assessments of fertility  ................................................. 53 
8.4.4 Other safety evaluations  ........................................................................ 53 
8.4.5 Appropriateness of safety measurements  .............................................. 54 
8.5 Additional assessments  .......................................................................................... 54 
  54 
8.5.2 Pharmacokinetics  .................................................................................. 56 

[COMPANY_001]  Confidential  Page 4 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 8.5.[ADDRESS_1014009]- study treatment  .......................................................... 60 
10 Safety monitoring and reporting  ........................................................................................ 60 
10.1 Definition of adverse events and reporting requirements ...................................... 60 
10.1.1 Adverse events ...................................................................................... 60 
10.1.2 Serious adverse events  .......................................................................... 62 
10.1.3 SAE reporting........................................................................................ 63 
10.1.4 Pregnancy reporting .............................................................................. 64 
10.1.5 Reporting of study treatment errors including misuse/abuse ................ 64 
10.2 Additional Safety Monitoring  ................................................................................ 65 
10.2.1 Liver safety monitoring  ......................................................................... 65 
10.2.2 Renal safety monitoring  ........................................................................ 66 
10.2.3 Data Monitoring Committee  ................................................................. 66 
11 Data Collection and Database management  ...................................................................... 66 
11.1 Data collection  ....................................................................................................... 66 
11.2 Database management and quality control ............................................................ 67 
11.3 Site monitoring  ...................................................................................................... 67 
12 Data analysis and statistical methods  ................................................................................ 68 
12.1 Analysis sets .......................................................................................................... 68 
12.2 Participant demographics and other baseline characteristics  ................................. 69 
12.3 Treatments  ............................................................................................................. 69 
12.4 Analysis of the primary endpoint(s)/estimand(s) .................................................. 69 
12.4.1 Definition of primary endpoint(s)/estimand(s)  ..................................... 69 
12.4.2 Statistical model, hypothesis, and method of analysis .......................... 70 
12.4.3 Handling of remaining intercurrent events of primary estimand  .......... 70 
12.4.4 Handling of missing values not related to intercurrent event  ............... 71 
12.4.5 Sensitivity analyses for primary endpoint/estimand  ............................. 71 

[COMPANY_001]  Confidential  Page 5 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 12.4.6 Supplementary analysis ......................................................................... 71 
12.4.7 Supportive analyses  ............................................................................... 71 
12.5 Analysis of secondary endpoints/estimands  .......................................................... 71 
12.5.1 Pharmacokinetics  .................................................................................. 71 
12.5.2 PK/PD relationships  .............................................................................. 71 
12.5.3 Immunogenicity  .................................................................................... 71 
  72 
12.7 Interim analyses  ..................................................................................................... 72 
12.8 Sample size calculation .......................................................................................... 72 
13 Ethical considerations and administrative procedures  ...................................................... 72 
13.1 Regulatory and ethical compliance ........................................................................ 72 
13.2 Responsibilities of the investigator and IRB/IEC  .................................................. 72 
13.3 Publication of study protocol and results............................................................... 72 
13.4 Quality Control and Quality Assurance  ................................................................. 73 
14 Protocol adherence  ............................................................................................................ 73 
14.1 Protocol amendments ............................................................................................. 73 
15 References  ......................................................................................................................... 74 
16 Appendices ........................................................................................................................ 76 
16.1 Appendix 1: Clinically notable laboratory values and vital signs ......................... 76 
16.2 Appendix 2: Liver event and laboratory trigger definitions & follow-up 
requirements .......................................................................................................... 78 
16.3 Appendix 3: Specific Renal Alert Criteria and Actions and Event Follow-up ...... 82 
16.4 Appendix 4: Hepatitis B serology results and interpretation ................................. 83 
16.5 Appendix 5: Blood Logs ........................................................................................ 84 
  88 
  93 
  94 
  96 
16.10 Appendix 10: Satisfaction with self-injection using a prefilled syringe 
questionnaire .......................................................................................................... 97 
16.11 Appendix 11: Study design of core study CCFZ533B2201 .................................. [ADDRESS_1014010] of tables  
Table 2 -1 Objectives and related endpoints .......................................................... 18 
Table 4 -1 Potential risks associated with CFZ53  .................................................. 24 
Table 6 -1 Investigational and control drug ............................................................ 29 
Table 6 -2 Prohibited medication  ........................................................................... 32 

[COMPANY_001]  Confidential  Page 6 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 Table 6 -3 Blinding and unblinding plan ................................................................ 35 
Table 8 -1 Assessment Schedule  ............................................................................ 44 
Table 8 -2 Assessment and Specifications  ............................................................. 51 
Table 8 -3 Laboratory Evaluations  ......................................................................... 52 
Table 10-1 Guidance for capturing the study treatment errors including misuse/abuse ......................................................................................... 65
 
Table 16-1 Clinically notable laboratory values and vital signs  ............................. 76 
Table 16-2 Liver event and laboratory trigger definitions  ...................................... 78 
Table 16-3 Follow up requirements for liver events and laboratory triggers  .......... 78 
Table 16-4 Specific Renal Alert Criteria and Actions and Event Follow -up .......... 82 
Table 16-5 (A) - Blood Logs  ................................................................................... 84 
Table 16-6 (B) - Blood Logs  ................................................................................... [ADDRESS_1014011] of figures  
Figure 3-1 TWINSS extension study (CCFZ533B2201E1) design ........................ 21 
Figure 4-1 Iscalimab doses and regimen  ................................................................ 22 
Figure 6-1 IRT Algorithm for treatment reassignment  ........................................... 31 
 

[COMPANY_001]  Confidential  Page 7 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 List of abbreviations  
ACR  American College of Rheumatology  
ADA Anti-drug antibody  
AE Adverse Event  
ALP Alkaline Phosphatase  
ALT Alanine Aminotransferase  
  
AST Aspartate Aminotransferase  
ATC Anatomical Therapeutic Classification  
BMI Body Mass Index  
BP Blood Pressure  
BUN  Blood Urea Nitrogen  
  
CFR Code of Federal Regulation  
ClinRO  Clinician Reported Outcomes  
CMO&PS  Chief Medical Office and Patient Safety  
CMV  Cytomegalovirus ( Human - Cytomegalovirus)  
CNS  Central nervous system  
CO Country Organization  
COA  Clinical Outcome Assessment  
COVID -19 Coronavirus Disease 2019  
CRF Case Report/Record Form (paper or electronic)  
CRP  C-reactive protein  
CSR  Clinical study report  
CTC Common Terminology Criteria   
Ctrough  Trough concentration  
CV coefficient of variation  
DMARD  Disease modifying antirheumatic drug  
DMC  Data Monitoring Committee  
dsDNA  double -stranded deoxyribonucleic acid  
ECG  Electrocardiogram  
eCOA  Electronic Clinical Outcome Assessment  
eCRF  Electronic case report form  
EDC  Electronic Data Capture  
EOS  End of study  
   
eSource  Electronic Source  
ESR Erythrocyte sedimentation rate  
ESSDAI  EULAR  Sjögren's syndrome disease activity index  
ESSPRI  EULAR  Sjögren's syndrome patient reported index  
EULAR  European League Against Rheumatism  
  

[COMPANY_001]  Confidential  Page 8 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 FAS Full analysis set  
FDA Food and Drug Administration  
GCP  Good Clinical Practice  
GCS  Global Clinical Supply  
GGT  Gamma -glutamyl transferase  
HBc HB core antigen  
HBs HB surface antigen  
HBsAg  Hepatitis B surface antigen  
HBV Hepatitis B Virus  
hCG Human chorionic gonadotropin  
HDL High density lipoprotein  
i.v. intravenous  
IB Investigator’s Brochure  
ICF Informed Consent Form  
ICH International Council for Harmonization of Technical Requirements for 
Pharmaceuticals for Human Use  
  
IEC Independent Ethics Committee  
IFU Instructions for use  
IgG Immunoglobulin G  
IgM Immunoglobulin M  
IMP Investigational Medicinal Product  
IN Investigator Notification  
INR International Normalized Ratio  
IRB Institutional Review Board  
IRT Interactive Response Technology  
IUD Intrauterine device  
IUS Intrauterine system  
LDH lactate dehydrogenase  
LDL Low density lipoprotein  
LFT Liver function test  
LLOQ  lower limit of quantification  
LN Lupus nephritis  
LVV Large vessel vasculitis  
mAb Monoclonal antibody  
MedDRA  Medical dictionary for regulatory activities  
mg milligram(s)  
mL milliliter(s)  
MMF  Mycophenolate Mofetil  
NHP  Non-human primates  
NSAID  Nonsteroidal anti -inflammatory drugs  
OL Open -label  

[COMPANY_001]  Confidential  Page 9 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
   
PCR  Polymerase chain reaction  
PD Pharmacodynamic(s)  
PFS Prefilled syringe  
  
  
PK Pharmacokinetic(s)  
PNS Peripheral nervous system  
PoC Proof of Concept  
PRO  Patient Reported Outcomes  
pSS primary  Sjögren's syndrome   
PT prothrombin time  
PTLD  Post-transplantation proliferative disorder   
PTT Partial thromboplastin time  
Q2W  every 2 weeks, bi -weekly  
QMS  Quality Management System  
QTcF  QT interval corrected by [CONTACT_6550]’s formula  
RA Rheumatoid arthritis  
  
s.c. subcutaneous  
SAE Serious Adverse Event  
SAF Safety Set  
SAP Statistical Analysis Plan  
SD standard deviation  
SGOT  Serum Glutamic Oxaloacetic Transaminase  
SGPT  Serum Glutamic Pyruvic Transaminase  
SjS Sjögren's Syndrome   
SLE Systemic lupus erythematosus  
SoC Standard -of-care 
SOP  Standard operating procedures  
SSA Sjögren's syndrome -related antigen A  
  
S[LOCATION_003]R  Suspected Unexpected Serious Adverse Reaction  
TD Study Treatment Discontinuation  
TDAR  T cell -dependent antibody response   
TEAE  Treatment emergent adverse events  
TFQ Trial feedback questionnaire  
TMDD  Target mediated drug disposition  
ULN upper limit of normal  
VAS Visual analog scale  
WBC  white blood cell(s)  
WHO  World Health Organization  

[COMPANY_001]  Confidential  Page 10 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 WOCBP  Women of child -bearing potential  
[COMPANY_001]  Confidential  Page 11 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 Glossary of terms  
Assessment  A procedure used to generate data required by [CONTACT_90166]  A specific group of participants fulfilling certain criteria and generally treated at 
the same time  
Control drug  A study drug (active or placebo) used as a comparator to reduce assessment bias, preserve blinding of investigational drug, assess internal study validity, 
and/or evaluate comparative effects of the investigational drug  
Dosage Dose of the study treatment given to the participant in a time unit (e.g. 100 mg 
once a day, 75 mg twice a day)  
Electronic Data 
Capture (EDC)  Electronic data capture (EDC) is the electronic acquisition of clinical study 
data using data collection systems, such as Web -based applications, 
interactive voice response systems and clinical laboratory interfaces. EDC includes the use of Electronic Case Report Forms (eCRFs) which are used to 
capture data transcribed from paper source forms used at the point of care  
Enrollment  Point/time of participant entry into the study at which informed consent must 
be obtained  
Estimand   A precise description of the treatment effect reflecting the clinical question posed by [CONTACT_6553]. It summarizes at a population- level what the 
outcomes would be in the same patients under different treatment conditions being compared. Attributes of an estimand include the population, variable (or endpoint) and treatment of interest, as well as the specification of how the 
remaining intercurrent events are addressed and a population-level summary 
for the variable.  
Intercurrent events  Events occurring after treatment initiation that affect either the interpretation or 
the existence  of the measurements associated with the clinical question of 
interest.  
Investigational 
drug/ treatment  The drug whose properties are being tested in the study  
Medication number  A unique identifier on the label of medication kits  
Other treatment  Treatment that may be needed/allowed during the conduct of the study (i.e. 
concomitant or rescue therapy)  
Participant  A trial participant (can be a healthy volunteer or a patient)  
Participant number  A unique number assigned to each participant upon signing the informed 
consent. This number is the definitive, unique identifier for the participant and 
should be used to identify the participant throughout the study for all data 
collected, sample labels, etc. 
Period  The subdivisions of the trial design (e.g. Screening, Treatment, Follow -up) 
which are described in the Protocol. Periods define the study phases and will 
be used in clinical trial database setup and eventually in analysis  
Personal data Participant information collected by [CONTACT_157058]. This data includes 
participant identifier information, study information and biological samples.  
Premature 
participant 
withdrawal  Point/time when the participant exits from the study prior to the planned 
completion of all study drug administration and/or assessments; at this time all 
study drug administration is discontinued and no further assessments are 
planned  
Randomization 
number  A unique identifier assigned to each randomized participant  
[COMPANY_001]  Confidential  Page 12 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 Screen Failure A participant who did not meet one or more criteria that were required for 
participation in the study  
Source 
Data/Document  Source data refers to the initial record, document, or primary location from 
where data comes. The data source can be a database, a dataset, a 
spreadsheet or even hard -coded data, such as paper or eSource  
Study treatment  Any drug or combination of drugs or intervention administered to the study participants as part of the required study procedures; includes investigational 
drug(s), control(s) or background therapy  
Study treatment 
discontinuation When the participant permanently stops taking any of the study drug(s) prior 
to the defined study treatment completion date (if any) for any reason; may or 
may not also be the point/time of study discontinuation  
Treatment 
arm/group  A treatment arm/group defines the dose and regimen or the combination, and 
may consist of 1 or more cohorts.  
Variable (or 
endpoint)  The variable (or endpoint) to be obtained for each participant that is required 
to address the clinical question.  The specification of the variable might include 
whether the participant experiences an intercurrent event.  
Withdrawal of 
study consent 
(WoC)  Withdrawal of consent from the study occurs only when a participant does not want to participate in the study any longer and does not allow any further 
collection of personal data   
 
 
               
[COMPANY_001]  Confidential  Page 13 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 Amendment 1 ( 17-Feb- 2021)  
Amendment rationale  
The main purpose of this protocol amendment is to include an additional assessment time point 
as part of the Interactive Response Technology (IRT) algorithm criteria for participant rollover from the TWINSS core study (CCFZ533B2201) to extension study. ESS DAI and ESSPRI 
scores at Week [ADDRESS_1014012] missed their ESSDAI (Cohort 1 and Cohort 2) and/or ESSPRI (Cohort 2) assessments at Week 4  to be considered for inclusion in 
the extension study if these assessments were completed at Week 0 (baseline) of the core study.  
Specific guidance concerning public health emergency situations as declared by [CONTACT_297206] (i.e., pandemic, epi[INVESTIGATOR_6519]) has been included in Section  4.6, as well as mitigation procedures to ensure participant safety and trial integrity in 
the relevant sections.  At the time of this amendment, [COMPANY_001] has performed a study -specific 
medical and safety risk assessment and concluded that based on the current data, the benefit/risk of iscalimab due to COVID -[ADDRESS_1014013] been updated in the amended protocol: 
• Section 3 and Section 6.1.3 updated to include the use of ESSDAI (Cohort 1 and Cohort 
2) and ESSPRI (Cohort 2) scores at Week 0 for the IRT algorithm if a score is missing 
at Week 4 of the core study.  
• Section 4.1 text updated to clarify rationale for study design. 
• Section 4.[ADDRESS_1014014] been updated accordingly. 
• Section 5.2 exclusion criterion #6 added to exclude a participant rolling over from the 
core study to the extension study in the case of a missing ESSDAI (Cohort 1 and Cohort 2) or ESSPRI (Cohort 2) score in the core study at Weeks 0 and 4 or Weeks 40 and 48.    
• Figure 6-1 IRT Algorithm for treatment reassignment updated to include the use of 
ESSDAI (Cohort 1 and Cohort 2) and ESSPRI (Cohort 2) scores at Week 0 if a score is missing at Week 4 of the core study.  
• Section 6.3.2 updated to clarify the process for transfer of ESSDAI and ESSPRI data 
from the core study to the extension study IRT database. 
• Section 6.4 deletion of text to clarify that blood samples for PK, immunogenicity and 
.  
• Section 6.5.2 and Section 8  updated to clarify the treatment period and follow -up period 
of the extension study.  

[COMPANY_001]  Confidential  Page 14 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 • Section 6.7.2 updated with following text for more clarity: “ Prior to self- administration 
at home, participants should contact [CONTACT_093]/site staff in the case they are experiencing any AE/SAEs or have any concerns or there have been changes to the ongoing c oncomitant medications .”   
• Section 7 updated to include information on the digital injection care management 
device.   
• Section 8.3 Instructions were added to use paper PRO a s a back -up solution i n case of 
case of device(s) failure.    
• Table 8 -3 Laboratory evaluations ( Section 8.4.1 ) updated to remove FSH listed under 
additional assessments as fertility will not be assessed in the extension study.  
• Section [IP_ADDRESS] text added to clarify that the PFS Questionnaire feedback is anonymous 
and individual participant level responses will not be reviewed by [CONTACT_4718]. 
• Section 10.2.2, Table [ADDRESS_1014015] units 
for potassium and protein -creatinine ratio parameters.  
• Section 16.5  Appendix 5: Blood Logs updated to align the blood volumes as per central 
laboratory requirements.  
Changes to specific sections of the protocol are shown in the track changes version of the protocol using strike through red font for deletions and red underlined for insertions.  
IRBs/IECs  
A copy of this amended protocol will be sent to the Institutional Review Board (IRBs)/Independent Ethics Committee (IECs) and Health Authorities.  
The changes described in this amended protocol require IRB/IEC and Health Authority approval according to local regulations prior to implementation.  
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this protocol amendment.  
  
[COMPANY_001]  Confidential  Page 15 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 Protocol summary  
Protocol number  CCFZ533B2201E1  
Full Title  A TWINSS extension trial to evaluate the safety and tolerability of CFZ533 (iscalimab) at two dose levels administered subcutaneously in patients 
with Sjögren’s Syndrome  
Brief title  Study of safety and tolerability of CFZ533 in patients with Sjögren’s 
Syndrome  
Sponsor and Clinical Phase  [COMPANY_001]  
Phase IIb  
Investigation type  Biological  
Study type  Interventional  
Purpose and 
rationale  The purpose of this 1- year extension study is to provide additional safety 
and tolerability information of the two doses of CFZ533 (iscalimab 600 mg 
and 300 mg) administered via prefilled syringes (PFS).   
Primary Objective(s)  The primary objective of this study is to evaluate the safety and tolerability 
of iscalimab at two dose levels (600 mg and 300 mg) in patients with 
Sjögren’s Syndrome, who participated in the TWINSS core study, 
CCFZ533B2201.  
Secondary Objectives  Objective 1: To assess the pharmacokinetics (PK trough levels) and dose-exposure relationship of iscalimab  
Objective 2: To assess immunogenicity of iscalimab  
Study design Study CCFZ533B2201E1 is a multicenter extension study. Study blinding 
for the extension study will be maintained until final database lock of the 
core study, CCFZ533B2201, upon which the participants and Investigators 
will be unblinded, making it an open-l abel study through Week 120 (end of 
study visit).  
Study population  The study population will consist of approximately 160 male and female 
participants (≥18 years old at the time of consent) who completed the core 
study (CCFZ533B2201) and who meet the inclusion/exclusion criteria.  
Key Inclusion 
criteria  • Participants must have participated in the TWINSS core study, CCFZ533B2201, and must have completed the entire treatment period up to Week 48 and the follow- up period up to Week 60  
• In the judgement of the Investigator, participants must be expected to 
clinically benefit from continued iscalimab therapy  
Key Exclusion 
criteria  • Sjögren’s Syndrome overlap syndromes where another autoimmune 
rheumatic disease constitutes the principle illness, specifically:  
• Moderate- to-severe active systemic lupus erythematosus (SLE) with 
anti-dsDNA positivity and renal involvement, or other organ 
involvement that impedes on ability to score ESSDAI domains  
• Active rheumatoid arthritis (RA) that impedes on the ability to score the ESSDAI articular domain  
• Systemic sclerosis  
• Any other concurrent connective tissue disease (e.g., lupus nephritis (LN), large vessel vasculitis (LVV), Sharp syndrome (mixed connective 
tissue disease) that is active and requires immunosuppressive 
[COMPANY_001]  Confidential  Page 16 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 treatment outside the scope of this trial and would impede on Sjögren's 
Syndrome organ domain assessments  
• Use of other investigational drugs other than iscalimab during the core 
study  
• Active  uncontrolled viral, bacterial or other infections requiring systemic 
treatment at the time of enrollment, or history of recurrent clinically 
significant infection or of bacterial infections with encapsulated organisms  
• Missing ESSDAI (Cohort 1 and Cohort 2) or ESSPRI (Cohort 2) scores 
in the core study at Weeks 0 and 4 or Weeks 40 and 48  
Study treatment  CFZ533 (iscalimab) will be administered as two 2 mL bi -weekly 
subcutaneous (Q2W s.c.) injections in prefilled syringes (PFS).  
Participants will be re -assigned to one of the following two treatment arms:  
• Arm 1  - Iscalimab 600 mg s.c. Q2W  
• Arm 2  - Iscalimab 300 mg s.c. Q2W  
Pharmacodynamic 
assessments   
Pharmacokinetic 
assessments  Trough iscalimab plasma concentrations  
Key safety 
assessments  Adverse event monitoring, physical examinations, vital signs, monitoring of 
laboratory markers in blood and urine, monitoring of . 
Other assessments  •  
•  
•  
•  
•  
•  
•  
•  
•  
•  
 
•  
Data analysis Descriptive statistics will be provided for this study.  
Summary statistics for continuous variables will include N, mean, standard 
deviation (SD), minimum, lower quartile, median, upper quartile, and 
maximum. Summary statistics for discrete variables will be presented in the 
number and percent of patients in ea ch category.  
Key words  Sjögren’s Syndrome, autoimmune disease, ESSDAI, ESSPRI, monoclonal antibody, anti -CD40, CFZ533, iscalimab, prefilled syringe (PFS), 
subcutaneous injection, TWINSS extension  

[COMPANY_001]  Confidential  Page 17 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 1 Introduction  
1.1 Background 
Sjögren's Syndrome (SjS) is a chronic autoimmune disease of unknown etiology, characterized by [CONTACT_741667]. Although primarily organ- specific for the lacrimal and salivary glands, the inflammatory process can target any 
organ ( Asmussen  et al 1996). Thus, the clinical features range from dryness, pain and fatigue 
affecting nearly all patients, to severe, extra- glandular and systemic involvement in a more 
limited subset. The increased B -cell activity underlying SjS also results in an increased risk for 
malignant transformation, with lymphoma development occurring in up to 5% of Sjögren's Syndrome (SjS) patients ( Ramos -Casals et  al 2005, Theander  et al 2011 ). Sjögren's Syndrome 
(SjS) is second only to rheumatoid arthritis (RA) in prevalence as a systemic autoimmune disease, with an estimated prevalence of 0.2% -0.5%. The disease affects mainly women with a 
female/male ratio of 9:1 and can occur at any age ( Qin et al 2015).  
Current standard of care (SoC) treatment for SjS patients is limited to symptomatic care for the mucosal signs and symptoms (dryness). Steroids and conventional disease -modifying 
antirheumatic drugs (DMARDs), although used in selected patients, have not been proven efficacious, and no pharmacologic intervention is effective against the severe, disabling fatigue. Hence, there are no approved treatments available for active, systemic disease.  
CFZ533 (iscalimab) is a fully human Fc -silenced, non -depleting, Immunoglobulin G1 (IgG1) 
anti-CD40 monoclonal antibody (mAb) that blocks the CD154- induced activation of CD40 
pathway signaling, thereby [CONTACT_741668]40 pathway signaling and activation of all  CD40+ 
cell types (B -cells, activated parenchymal cells, antigen presenting cells). The relevance of the 
CD40/CD154 pathway for autoimmunity and inflammation in multiple cell types and functions is well established ( Karnell et  al 2019). In the context of SjS, the most important molecular and 
cellular action of iscalimab is expected to be inhibition of T cell -dependent antibody response 
(TDAR) and disruption of germinal center formation in secondary lymphoid tissues in the affected sali vary glands. 
The therapeutic hypothesis was successfully tested in a first proof -of-concept (PoC) study of 
iscalimab in patients with primary Sjögren's Syndrome (pSS). Briefly , in this randomized 
controlled trial, the primary endpoint of European Sjögren’s Syndrome Disease Activity Index (ESSDAI) improvement was met, along with improvements in patient reported outcomes (PRO) including fatigue ( Fisher  et al 2017 ); please see current Iscalimab Investigator's 
Brochure (IB) for details. The overall risk/benefit profile was favorable, warranting continued development in this indication. 
Limited safety data are currently available for iscalimab in any indication that is under 
investigation. This extension study (CCFZ533B2201E1) will allow us to demonstrate the additional safety and tolerability of two doses (600 mg and 300 mg)  of treatment  with iscalimab 
in patients with Sjögren's Syndrome (SjS). 
1.2 Purpose 
Study CCFZ533B2201 (TWINSS) is a double -blinded Phase IIb study enrolling two distinct 
populations of patients with SjS and is defined as the "core study". Study CCFZ533B2201E1 
[COMPANY_001]  Confidential  Page 18 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 is designed as a 1 -year extension to the core study. The extension study will be open only to 
eligible participants from the TWINSS core study who, in the opi[INVESTIGATOR_689], may potentially derive clinical benefit from continued administration of CFZ533 (iscalimab).  The 
primary purpose of this 1- year extension study is to provide additional safety and tolerability 
information of the two doses of iscalimab (iscalimab 600 mg and 300 mg) administered via prefilled syringes (PFS). Additionally, this e xtension study will further explore the 
pharmacokinetics (PK) and efficacy of iscalimab 600 mg and 300 mg doses. Key additional safety data will be used to better understand the overall safety profile of iscalimab at two dose levels and potentially inform study design elements of subsequent clinical studies (i.e. Phase III). 
2 Objectives and endpoints  
Table 2-1 Objectives and related endpoints 
Objective(s)  Endpoint(s)  
Primary objective(s)  Endpoint(s) for primary objective(s)  
• To evaluate the safety and tolerability of iscalimab at two dose levels (600 mg and 
300 mg) in patients with SjS, who 
participated in the TWINSS core study, CCFZ533B2201
 • Incidence of Treatment -emergent adverse 
events (TEAEs)/ serious adverse events 
(SAEs)  
Routine hematology and clinical chemistry 
laboratory test results at analysis visits up to 
end of study  
Vital signs at analysis visits up to end of 
study  
Secondary objective(s)  Endpoint(s) for secondary objective(s)  
• To assess the pharmacokinetics (PK trough levels) and dose -exposure relationship of 
iscalimab  • Free iscalimab concentration in plasma during the treatment (Ctrough) and follow- up 
(up to end of study)  periods   
• To assess immunogenicity of iscalimab  • Incidence of anti -iscalimab antibodies in 
plasma at analysis visits up to end of study  

[COMPANY_001]  Confidential  Page 19 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 2.1 Primary estimands  
Not applicable.  
2.2 Secondary estimands  
Not applicable. 
3 Study design  
TWINSS Core Study (CCFZ533B2201) Design  
TWINSS is a basket trial consisting of two distinct study parts termed Cohort 1 and Cohort 2. Cohort 1 is a randomized, double-blind, placebo-controlled, parallel group, dose-range finding study, planned to enroll approximately 160 participants. Cohort 2 i s a randomized, double -
blinded, placebo- controlled proof -of-concept study, planned to enroll approximately 100 
participants.  
During a 6- week screening period, all participants fulfilling the American College of 
Rheumatology/European League Against Rheumatism (ACR/EULAR) 2016 classification criteria will be assessed for all 12 ESSDAI domains and will be randomized to Cohort 1 (Arms A, B, C and D) or Cohort 2 (Arms E and F) accordingly (refer to CCFZ533B2201 core study protocol for further details). The study design for the TWINSS core study is provided in Section  16.11. 
TWINSS Extension Study (CCFZ533B2201E1) Design  
Study CCFZ533B2201E1 is a continuation of the core study and is planned as a multicenter trial. This study will offer continuation of treatment for participants who have completed the core study and are deemed by [CONTACT_741669]. 
Enrollment will be determined by [CONTACT_741670]. It is 
estimated that approximately 160 participants from both Cohort 1 and Cohort 2 of the core study 

[COMPANY_001]  Confidential  Page 20 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 may choose to enter the extension study. Study blinding for the extension study will be maintained until final database lock of the core study, upon which the participants and Investigators will be unblinded, making it an open- label study through Week 120 (end of study 
visit). All visit numbers (in weeks) used in the extension study are relative to the baseline visit of the core study. The baseline for the extension study (Week 60E1) will be carried out on the same day as the Week 60 visit of the core study . For more details refer to Table 8 -1 
The extension study is a 48- week treatment study, with a safety follow -up period of 12 weeks 
(Figure 3-1). Participants who complete 48 weeks of treatment and the mandatory 12 weeks of 
follow -up in the core study are eligible to participate in the extension study. The 12 weeks of 
follow -up in the core study is considered mandatory to obtain PK data. The study will help to 
evaluate the sustainability of response (ESSDAI) after a year of treatment in the core study.  
Upon completion of treatment Period 2 (Week 48) of the core study, Investigators will use their clinical judgment to decide if it is beneficial for participants to continue with the extension study. All participants will be considered for participation in the extension study. A new Informed Consent must be signed before proceeding into the extension study. The participant should provide their informed consent prior to the start of the Week 60 assessments of the core study. 
The treatment will be offered in PFS in the extension study. This is a change from the core 
study, which used s.c. injections prepared from vials. During the treatment period, 25 treatment administration visits are planned, including a weekly loading regimen (Week 60E1, Week 61, Week 62) at the start of the treatment period.  
All participants enrolled in the extension study will receive a weekly loading regimen (Week 60E1, Week 61, Week 62) at the start of the treatment period followed by a s.c. maintenance 
regimen (600 or 300 mg s.c. every 2 weeks (Q2W)). One administration eq uals two s.c. 
injections. Refer to Section  4.2 for more details on dosages of the weekly loading regimen in 
both arms. 
To maintain extension study blinding until final database lock of the core study, an Interactive 
Response Technology (IRT) algorithm will be used to re -assign participants to either iscalimab 
600 mg (Arm 1) or 300 mg (Arm 2) s.c. Q2W in the extension study using ESSDAI (Cohort 1 and Cohort 2) and ESSPRI (Cohort 2) scores from predefined time points (Week 4 (or Week 0 if a score is missing at Week 4) and Week 48 (or Week 40 if a score is missing  at Week 48) ) in 
the TWINSS core study  (refer to Section 6.1.3 for further details). 
Participants will be instructed in detail how to self- administer the s.c. injection using the PFS 
formulation. Each injection will be administered into an appropriate injection site of the body (thighs, arms, or abdomen). For the first four visits of the study (through Week 64), all injections will be performed at the study site. If a participant had good safety and tolerability, with no indication of hypersensitivity or other acute reactions from the previous doses, starting from Week 66, the participant is allowed to self -administer the study treatment at home according to 
the assessment schedule ( Table 8 -1). The participant may continue to present at 2 week intervals 
to the study site for injection administrations, based on the participant's preference and the Investigator's judgment. Site staff will administer the injection to participants who are not able  
or unwilling to self- administer the PFS injection. The treatment period is from Week 60E1 to 
Week 108. 
[COMPANY_001]  Confidential  Page 21 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 Figure 3-1 TWINSS extension study (CCFZ533B2201E1) design 
 
 
4 Rationale  
4.1 Rationale for study design  
This 1 -year extension study will provide additional safety data for two doses of iscalimab (600 
mg and 300 mg). This study will also provide continued administration of iscalimab for participants that as per Investigator may potentially derive clinical ben efit after completing the 
core study. The extension study will provide additional key safety data for the two doses 
of iscalimab to better understand the overall safety of iscalimab and potentially inform study design elements of subsequent clinical studies (i.e., Phase III).  The study will allow for the 
assessment of  continued evaluation of efficacy and tolerability. Furthermore, digital data 
collected as part of the extension study will build on existing digital data for further validation.  
A follow -up period of 12 weeks ([ADDRESS_1014016] dose) is required to reach sub-
pharmacological exposures after completion of dosing and was estimated taking into consideration the non- linear pharmacokinetics (target -mediated disposition) of iscalim ab - see 
Section  4.[ADDRESS_1014017] the integrity of the data in the ongoing core study. Participants can exit the study upon their own wish or based on advice of the Investigator at any time.  
[COMPANY_001]  Confidential  Page 22 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 4.1.1 Rationale for choice of background therapy 
Local remedies for symptom relief and systemic background medication as per local practice is allowed, as long as participants are on stable dose ( Section  6.2.1) and in accordance with the 
inclusion/exclusion criteria.  
4.2 Rationale for dose/regimen and duration of treatment  
CFZ533 (iscalimab) [ADDRESS_1014018] 3 doses (Weeks 60E1, 61 and 62); then, from Week 64, iscalimab will be administered s.c. bi -weekly 
(every other week or Q2W). This is illustrated in Figure 4 -1 for Arm 1 (iscalimab 600 mg 
maintenance regimen) and Arm 2 (iscalimab 300 mg maintenance regimen).  
• For participants assigned to the iscalimab 600 mg maintenance regimen (Arm 1), the loading doses are 600 mg on Week 60E1, 61 and 62, followed by a bi-weekly maintenance regimen at 600 mg. 
• For participants assigned to the iscalimab 300 mg maintenance regimen (Arm 2), the loading doses are [ADDRESS_1014019] to CD40 -mediated elimination (or target -mediated drug disposition 
(TMDD)), and the level of expression of CD40 receptors in target tissues has the potential to affect exposure to iscalimab, and ultimately target engagement. High CD40 expression may be associated with high elimination rate of iscalimab and loss of CD40 -CD154  (CD40 ligand) 
pathway blockade if CD40 receptors are not fully saturated. 
The proposed loading regimen is aiming to rapi[INVESTIGATOR_741658]40 receptor saturation and 
minimal CD40 -mediated elimination, in conditions where CD40 expression might be enhanced 
and additionally also to rapi[INVESTIGATOR_741659] -state conditions for iscalimab 
concentration in plasma. 
[COMPANY_001]  Confidential  Page 23 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 The 3 weekly loading doses of iscalimab in SjS patients are guided by [CONTACT_741671]- of-concept (PoC) Study CCFZ533X2203 in pSS. Based on these results the loading and 
further maintenance regimen will rapi[INVESTIGATOR_741660] c exposures above the 
threshold of 40 μg/mL for a broad population. This threshold was associated with complete suppression of germinal center development in cortical B cell areas of lymph nodes and T cell dependent antibody response in non-human primates (NHP).  
As demonstrated in the PoC Study CCFZ533X2203 in pSS, a single s.c. dose of 600 mg iscalimab at Day 1 will deliver plasma concentrations generally above 40 μg/mL after 1 week. Subsequent weekly doses on Week 61 and 62 in Arms 1 and 2 are expected  (i) to ma intain 
CFZ533 plasma levels above 40 μg/mL, and (ii) to deliver iscalimab trough levels that are close to expected steady state conditions.  
Further supportive arguments on the selected loading dosing regimen are provided in the Rationale for dose/regimen and duration of treatment of the TWINSS core study protocol (refer to Section 4 of the core study protocol). 
Rationale for maintenance regimen  
The maintenance regimen of 600 mg s.c. Q2W is expected to provide a median steady state 
trough plasma level at about 144 μg/mL (90% of the population within 282 - 46 μg/mL), in the 
upper range of trough levels observed in the PoC Study CCFZ533X2203-Cohort 2 (i.v. 
regimen; these concentrations were associated with clinical efficacy and suppression of a biologically relevant biomarker CXCL13 - a marker of germinal center activity).  
The maintenance regimen of 300 mg s.c. Q2W is expected to deliver a median steady state trough plasma level at about 54 μg/mL (90% of the population within 125 - 0.1 μg/mL), with a 
reasonable chance to show efficacy in SjS.  
The between subject variability in exposure within the two treatment arms (to a lesser extent in 
the 600 mg treatment arm) is likely to depend on the biology of CD40 in target tissues (expression level, turnover) and its potential modulation during the treatment period.  
Rationale for the duration of the safety follow -up period (target engagement after the last 
dose)  
Based on predicted median CFZ533 plasma concentration -time profile at [ADDRESS_1014020] dose, iscalimab plasma concentrations are expected to 
drop below 20 μg/mL with no expected pharmacodynamic activity in target ti ssues (e.g., 
germinal centers; data from non -human primates - please see current IB).  
A 12 -week follow -up period ([ADDRESS_1014021] dose) has been selected for the study and 
is justified to monitor for any related serious adverse events (SAE).  
4.3 Rationale for choice of control drugs (comparator/placebo) or 
combination drugs  
There is no placebo or active control group in this study given the purpose and main objectives 
are to extend treatment of participants who completed the core study. The use of two different doses of iscalimab (iscalimab 600 mg and 300 mg) will allow evaluation of both doses in terms of safety, tolerability and sustainability of clinical benefits. Placebo injection will be  provided 
[COMPANY_001]  Confidential  Page 24 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 to maintain  blinding until the final database lock of the core study to protect the integrity of the 
data in the ongoing core study. For more details refer to Section  6.1.1. 
4.4 Purpose and timing of interim analyses/design adaptations  
There is no interim analysis planned for the study. The final analysis of the study will be performed at the end of the study. The end of the study is defined when all re -assigned 
participants have completed Week 120 or discontinued earlier. The extension study may be amended if deemed necessary based on the results of the TWINSS core study Week 24 primary analysis.  
4.5 Risks and benefits  
The risk to participants in this trial may be minimized by [CONTACT_178438] (refer to Section  5) and study procedures, as well as close clinical monitoring.  
Risks:  
The potential safety concerns in humans and the investigator guidance related to administration of CFZ533 are based on the data from the available clinical trials with CFZ533, preclinical and toxicological data, as well as experience with other compounds of the same class.  
In the indication of SjS there are no identified risks beyond those described in detail in Section 7 of the current edition of the CFZ533 IB. Important Potential Risks for CFZ533 are summarized in Table 4 -1 below: 
Table 4-[ADDRESS_1014022] adequate 
preformed antibody to maintain protective humoral response for extended periods of time (months). The participants will be monitored during the study for any signs and symptoms of infections 
including serology tests for cytomegalovirus (CMV; human -cytomegalovirus) infection.  
Risk [ADDRESS_1014023] been 
observed in NHP studies, or in clinical trials in healthy volunteers or participants where CFZ533 was evaluated.  
Hematology will be regularly monitored for changes consistent with a lymphoproliferative disorder. A 
physical examination will be performed to check for unusual lymphadenopathy in the absence of 
infection.  
Risk 3 Thrombophilia/ Thrombosis  
[COMPANY_001]  Confidential  Page 25 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 There is a hypothetical risk for thromboembolic complications when targeting this co -stimulatory 
pathway. This risk is based on clinical results from previous compounds (e.g. BG9588, IDEC -131) 
which have targeted CD154 (CD40 ligand) and resulted in a fatal hyper -coagulation phenotype.  
Although the risk is theoretical, hematologic and coagulation parameters will be monitored in the 
current study. Furthermore, participants with conditions such as antiphospholipid syndrome, who 
are at a higher risk for thromboembolism, will be excluded unless they are receiving antithrombotic prophylaxis. CFZ533 binds to CD40 receptor and is Fc- silent mAb hence does not appear to carry 
the same risk of thrombosis. Both preclinical and clinical data from an extensive Phase [ADDRESS_1014024] the drug itself, neutralizing or not.  
Samples will be collected during study to assess immunogenicity. Immunogenicity will be monitored 
during clinical development and the consequences of an immune response to CFZ533 could be correlated with, a loss of exposure (PK), a loss of peripheral CD40 receptor occupancy (PD), and/or 
the appearance of immune related adverse events including injection site reactions.  
Risk 5 Vaccination Failure 
Vaccination of participants during treatment with CFZ533 and prior to clearance of the antibody is likely to result in therapeutic failure (i.e., non- protective antibody titers) due to the pharmacologic 
activity of the antibody. Administration of live attenuated vaccines should be avoided while receiving 
CFZ533 treatment and for at least 14 weeks thereafter.  
One fatal event (potential CMV infection) was reported in the CCFZ533X2202 clinical trial in 
Lupus nephritis, suspected to be related to the study medication by [CONTACT_737]. 
The event was confounded by [CONTACT_741672], low lymphocyte count at baseline and concomitant immunosuppressive medications like MMF and prednisolone. The ultimate cause of death remains unclear; however, the events leading to fatal outcome could have been associated with the CMV infection and/or with a bacterial superinfection, and a role of study drug cannot be excluded. 
Currently, the causal effect of CFZ533 remains unclear, however, active viral infections do 
remain a potential risk. Specific detection measures have been implemented to monitor the risk of CMV infection across the clinical development program for CFZ533. 
The infections including CMV are considered as an important potential risk for CFZ533 and 
will continue to be closely monitored and mitigated in the current study. 
Lastly, women of childbearing potential (WOCBP) must be informed that taking the study 
treatment may involve unknown risks to the fetus if pregnancy were to occur during the study. In order to participate in the study, they must adhere to the contraception  requirements outlined 
in the exclusion criteria. If there is any question that the participant will not reliably comply, they should not be entered or continue in the study. 
For further information on the above specific risks and other potential adverse effects of the 
compound please refer to Section 7 of the current edition of the CFZ533 IB. 
[COMPANY_001]  Confidential  Page 26 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 Benefits:  
The study design allows that all participants are treated with standard treatment for SjS, including systemic treatments such as hydroxychloroquine or immunosuppressive medicines where indicated, as long as the dose is kept stable ( Section  6.2.1) and the potential risks and 
benefits from these medicines are known. Based on the preliminary safety and efficacy data from the exploratory PoC study of iscalimab in pSS, it is possible that a number of participants in one or both iscalimab dose arms experience clinically important benefit from iscalimab treatment in the current study.  
4.6 Rationale for Public Health Emergency mitigation procedures  
During a Public Health emergency as declared by [CONTACT_6586] i.e. pandemic, epi[INVESTIGATOR_6519], mitigation procedures to ensure participant safety and trial integrity are listed in relevant sections. Notification of the Public he alth emergency should be discussed 
with [COMPANY_001] prior to implementation of mitigation procedures, and permitted/approved by [CONTACT_6588].  
[ADDRESS_1014025] of male and female participants ≥ 18 years, with SjS defined according to the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) 2016 classification criteria (Shiboski et  al 2017) who have completed the entire 
treatment period up to Week 48 and the mandatory 12 weeks follow -up period up to Week 60 
of the TWINSS core study. The study population has previously been described in detail in the core study protocol (refer to Section 5 of the core study protocol). Enrollment will be 
determined by [CONTACT_741670]. It is estimated that approximately [ADDRESS_1014026] meet all of the following criteria:  
1. Participants must have participated in the TWINSS core study, CCFZ533B2201, and must have completed the entire treatment period up to Week [ADDRESS_1014027] be obtained prior to participation in the extension study 
(i.e. before commencement of the Week 60 assessments of the core study)  
3. In the judgement of the Investigator, participants must be expected to clinically benefit 
from continued iscalimab therapy  
5.2 Exclusion criteria 
Participants meeting any of the following criteria are not eligible for inclusion in this study.  
1. Sjögren’s Syndrome overlap syndromes where another autoimmune rheumatic disease constitutes the principle illness, specifically:  
[COMPANY_001]  Confidential  Page 27 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 • Moderate- to-severe active systemic lupus erythematosus (SLE) with anti -dsDNA 
positivity and renal involvement, or other organ involvement that impedes on ability to score ESSDAI domains  
• Active rheumatoid arthritis (RA) that impedes on the ability to score the ESSDAI articular domain  
• Systemic sclerosis  
• Any other concurrent connective tissue disease (e.g., lupus nephritis (LN), large vessel vasculitis (LVV), Sharp syndrome (mixed connective tissue disease) that is active and requires immunosuppressive treatment outside the scope of this trial and 
would impede on Sjögren's Syndrome organ domain assessments 
2. Use of other investigational drugs other than iscalimab during the core study 
3. Active  uncontrolled viral, bacterial or other infections requiring systemic treatment at the 
time of enrollment, or history of recurrent clinically significant infection or of bacterial infections with encapsulated organisms 
4. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human Chorionic Gonadotropin (hCG) laboratory test  
5. Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 14 weeks after stoppi[INVESTIGATOR_741661]:  
• Total abstinence (when this is in line with the preferred and usual lifestyle of the 
patient). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception 
• Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy or tubal ligation at least six weeks before taking investigational drug. In case of oophorectomy alone, only when the reproductive status of th e woman has been confirmed by [CONTACT_6492]- up hormone level assessment  
• Male sterilization (at least 6 months prior to screening and confirmed as successful). For female patients in the study, the vasectomized male partner should be the sole partner for that patient. In case the vasectomized male partner is not the sole partner 
of the female patient, highly effective method of contraception must be applied 
(double barrier contraception is not sufficient)  
• Use of oral, (estrogen and progesterone), injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS) or other forms of hormonal contraception that have comparable efficacy (failure rate < 1%), for example hormone vaginal ring or transdermal hormone contraception. 
In case of use of oral contraception women should have been stable on the same pi[INVESTIGATOR_6522] a minimum of [ADDRESS_1014028] 
had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g., age appropriate, history of vasomotor symptoms) or have had surgical bilatera l 
oophorectomy (with or without hysterectomy), total hysterectomy or tubal ligation at least 
[COMPANY_001]  Confidential  Page 28 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by [CONTACT_741673].  
In case local regulations deviate from the contraception methods listed above, local regulations apply and will be described in the Informed Consent Form (ICF).  
6. Missing ESSDAI (Cohort 1 and Cohort 2) or ESSPRI (Cohort 2) scores in the core study at Weeks 0 and 4 or Weeks 40 and 48. 
6 Treatment 
6.1 Study treatment  
6.1.1 Investigational and control drugs 
The following drugs will be used in this study and will be administered in accordance with this protocol and where applicable, current local labeling. 
• CFZ533 (iscalimab) 300 mg provided in 2.0 mL PFS for s.c. injection  
• Placebo provided in 2.0 mL PFS for s.c. injection required for blinding 
• CFZ533 (iscalimab) 300 mg provided in 2.0 mL PFS for s.c. administration (open- label 
(OL) supplies) 
Before enrollment in this extension study, all participants electing to continue will sign an 
Informed Consent form. At extension study entry, participants/caregiver will be provided with detailed instructions for self -administration of the s.c. injection (Instructions for Use (IFU)) 
using the PFS formulation. In cases where the participant is not comfortable or confident that he/she can successfully self -administer the full dose of PFS in a home setting, a caregiver can 
be trained to administer the treatme nt to the participant. 
Each injection will be administered by [CONTACT_2299]/caregiver into an appropriate injection site of the body. Site staff will administer the injection to participants who are not able or unwilling to self- administer the PFS injection. For the first four visits at Weeks 60E1, 61, [ADDRESS_1014029] the choice of self -administration or injection by [CONTACT_84452] (once trained) at home or continuing with 
administration at site, based on personal preference and the Investigator's clinical judgment.  
The study is blinded until the final database lock of the core study to protect the integrity of the data in the ongoing core study. Once study unblinding occurs after the final database lock of the core study , the participants will continue to receive the same dose of iscalimab (either 600 
mg or 300 mg) and for those assigned to the 300 mg regimen, they will no longer receive the placebo PFS.  
Note: PFS do not need to be prepared at the site.  PFS will be packaged both as open- label and 
double- blind supplies. When the final database lock for the TWINSS core study is achieved, 
the extension study will become an OL study and the PFS will be provided in an OL manner with no further requirements for placebo PFS injections.  
[COMPANY_001]  Confidential  Page 29 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 [COMPANY_001] Global Clinical Supply (GCS) would provide the following IMPs in the trial. No other medication would be supplied by [CONTACT_275762]. 
Table 6-1 Investigational and control drug  
Investigational/ 
Control Drug 
(Name [CONTACT_6673])  Pharmaceutical Dosage Form  Route of Administration  Supply Type  Sponsor (global or local)  
CFZ533 300 
mg/2 mL  Solution for 
injection  Subcutaneous 
Use Blinded; PFS  [COMPANY_001] Pharma 
AG 
Placebo/2 mL  Solution for 
injection  Subcutaneous 
Use Blinded; PFS  [COMPANY_001] Pharma 
AG 
CFZ533 300 
mg/2 mL (OL)  Solution for 
injection  Subcutaneous 
Use Open -label; PFS [COMPANY_001] Pharma 
AG 
Instructions for administration of CFZ533 (iscalimab) and matching placebo are described in a separate manual.  
6.1.2 Additional study treatments 
No other treatment beyond investigational drug is included in this trial. 
6.1.3 Treatment arms/group 
No re -randomization is planned for the extension study. The treatment re -assignment for the 
extension study occurs at visit Week 60E1 which is the last visit of the core study (Week 60). 
Upon completion of the core study, Investigators will use their clinical judgment including responder definitions provided below to decide if it is beneficial for participants to continue with the extension study based upon response to therapy at the end of the treatment period of the core study. 
Participants will be re -assigned to one of the following two treatment arms: 
• Arm 1 - Iscalimab 600 mg s.c. Q2W 
• Arm 2 - Iscalimab 300 mg s.c. Q2W 
At Week 60 of the TWINSS core study, all eligible participants from the core study can opt to 
be enrolled in the extension study via IRT. The Week 60E1 visit will be performed on the same day once the Week 60 visit of the core study is completed by [CONTACT_291596]. The Investigator 
or his/her delegate will contact [CONTACT_741674]/exclusion criteria. An IRT algorithm will be programmed to assign the participant to blinded treatment in the extension study using ESSDAI (Cohort 1 and Cohort 2) and ESSPRI (Cohort 2) assessment scores from predefined time points in the TWINSS core study. 
• For participants rolling over from Cohort 1 in the TWINSS core study, the change in 
ESSDAI score between Week 4 and Week 48 will be used to determine if the participant responded to treatment in the core study. If an ESSDAI score is missing at Week 4 and/or 
Week 48, then Week 0 or Week 40 scores should be respectively used for the algorithm. A decrease of 3 points or more from Week 4 (or Week 0 if the ESSDAI score is missing at Week 4) will  classify the participant as a treatment responder in Cohort 1. 
[COMPANY_001]  Confidential  Page 30 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 • For participants rolling over from Cohort 2 in the TWINSS core study, a change in both ESSDAI and ESSPRI scores between Week 4 and Week 48 will be used to determine if the participant responded to treatment in the core study. If an ESSDAI or ESSPRI score is missing at Week 4 and/or Week 48, then Week 0 or Week 40 scores should be respectively used for the algorithm. A decrease of 1 point or more in both the ESSDAI and ESSPRI scores from Week 4 (or Week 0 if the ESSDAI or ESSPRI score is missing at Week 4) w ill classify the participant as a treatment responder in Cohort 2.    
Week [ADDRESS_1014030] and regression to the mean observed at study treatment initiation in clinical trials.  
Taking the treatment received during Treatment Period 2 of the TWINSS core study, and the responder status as the reference, the IRT algorithm will re- assign a dose level for extension 
study treatment. The maintenance treatment assigned for the extension study will be the same dose as in the core study or a higher dose level ( Figure 6-1).  
• Participants receiving iscalimab 600 mg s.c. Q2W or 300 mg s.c. Q2W in the core study and who meet the definition of a response will continue with the same dose in the extension study. 
• Participants receiving iscalimab 600 mg s.c. Q2W in the core study and who do not meet the definition of a response will continue in the extension study with the same dose. 
• Participants receiving iscalimab 150 mg s.c. Q2W in the core study and who meet the definition of a response will be re -assigned to 300 mg s.c. Q2W in the extension study. 
• Participants receiving iscalimab 300 mg s.c. Q2W or 150 mg s.c. Q2W in the core study and who do not meet the definition of a response will be re-assigned to 600 mg s.c. Q2W in the extension study. 
 
 
 
   
 
 
[COMPANY_001]  Confidential  Page 31 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 Figure 6-1 IRT Algorithm for treatment reassignment  
 
 
6.1.4 Treatment duration 
The planned duration of study treatment is 48 weeks. Participants may be discontinued from 
treatment earlier (see  Section  9.1.1 ). 
6.2 Other treatment(s)  
Participants experiencing disease signs and symptoms may receive short -term symptomatic 
care with over -the-counter, anti -inflammatory/analgesic agents such as nonsteroidal anti -
inflammatory drugs (NSAID) and paracetamol. Participants whose SjS disease signs and symptoms are not adequately controlled by [CONTACT_741675], and/or who suffer from more severe SjS disease manifestations not suitable for such treatment, may receive rescue therapy with corticosteroids, if determined by [CONTACT_741676] ( Section  6.2.3).  
There is currently no consensus on the definition of flare in SjS. With reference to the recently completed JOQUER trial in pSS ( Gottenberg et al 2014 ) that reported 12 flares among 120 
patients during 12 months, it is conceivable that < 10% of all patients in the current iscalimab trial will experience a deterioration (or ‘flare’) that warrants treatment escalation.  Treatment 
escalation would, for exam ple, be increasing the steroid dose, or introducing de novo an 
immunosuppressant agent like azathioprine.  Participants who require escape treatment (other 
than allowed rescue medications – see Section  6.2.3) must be discontinued from study 
medication, enter the safety follow -up period and follow the local standards for treatment of 
SjS worsening. In the absence of consensus guidelines for treatment of systemic manifestations in SjS, it is recommended to cons ult the SLE treatment guidelines as far as they pertain to the 
respective organ involvement observed in the trial (for example renal, nervous system or skin vasculitis).  

[COMPANY_001]  Confidential  Page 32 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 Any medication used to treat Adverse Events (AE) must be recorded on the Case Report Form (CRF).  
6.2.1 Concomitant therapy 
All medications, procedures, and significant non- drug therapi[INVESTIGATOR_014] (including physical therapy and 
blood transfusions) administered after the participant was enrolled into the study must be recorded on the appropriate Case Report Forms. 
Each concomitant drug must be individually assessed against all exclusion criteria/prohibited 
medication. If in doubt, the Investigator should contact [CONTACT_741677] -
assigning treatment for a participant or allowing a new medication  to be started. If the 
participant is already enrolled, contact [CONTACT_131343].  
Concomitant treatment may include standard of care for dry eye and dry mouth symptoms, such as the use of artificial tears and artificial saliva/salivary stimulants (e.g., cevimeline, pi[INVESTIGATOR_1227]) at the discretion of the treating physician. Amount and frequency of use should be recorded at each visit.  
Short term use of oral analgesics (NSAIDs, paracetamol) is permitted. Azathioprine (up to 150 mg/day), methotrexate (≤ 25 mg/week) and hydroxychloroquine (≤ 400 mg/day) are allowed as stable background medication defined as continued treatment ≥ 3 months w ithout dose 
adjustments. Steroids (prednisone or equivalent ≤ 10 mg/day) are allowed during the extension study and tapering is permitted at intervals not exceeding prednisone 2.5 mg/2 weeks.  
Pre-emptive therapy with lamivudine or entecavir is allowed for participants with Hepatitis B 
surface antigen (HBsAg) seroreversion while on study treatment. Similarly, CMV antiviral 
medication used as pre -emptive therapy is allowed for participants with detectable virus by 
[CONTACT_954].  
Note: Background and concomitant medications will not be provided by [CONTACT_741678].  
6.2.2 Prohibited medication 
Use of treatments displayed in the below table is not allowed in study periods as indicated. 
Table 6-2 Prohibited medication 
Medication  Prohibited in Study Period  Action to be taken  
Other experimental therapi[INVESTIGATOR_741662], participants should 
remain in the study and follow 
visit schedule  
Other biologics (for treatment of autoimmune diseases e.g., 
SjS, SLE, RA)  All 
Study treatment discontinuation 
required, participants should remain in study and follow visit 
schedule  
[COMPANY_001]  Confidential  Page 33 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 Medication  Prohibited in Study Period  Action to be taken  
DMARDs or other immune suppressive agents or changes in an existing DMARD regimen 
(hydroxychloroquine, 
methotrexate, azathioprine)  Treatment period  Study treatment discontinuation 
may be required on a case- by-
case basis  
Prednisone >10 mg (or 
equivalent other corticosteroid)  Treatment period  Study treatment discontinuation may be required on a case- by-
case basis  
Intravenous or oral 
cyclophosphamide; oral 
cyclosporine; oral MMF  All Study treatment discontinuation 
required, participants should 
remain in the study and follow 
visit schedule  
Existing co -medications 
observed to cause in an individual patient a major side 
effect of dry mouth/eyes. Examples include 
antihistamines, 
antidepressants, anticholinergics, sedatives, 
antipsychotic drugs, anti -
Parkinson agents  
A comprehensive guide to 
medications with documented 
effects on salivary gland function or symptoms has been 
published by [CONTACT_741679] 2017
 
(please see the footnote).  Treatment period  Study treatment discontinuation 
may be required on a case- by-
case basis  
Live/attenuated vaccine  During treatment and for at 
least 14 weeks thereafter  Study treatment discontinuation 
required, participants should 
remain in the study and follow 
visit schedule  
Wolff A, Joshi R, Ekström J, et al (2017) A guide to medications inducing salivary gland dysfunction, 
xerostomia, and subjective sialorrhea: A systemic review sponsored by [CONTACT_741680]; Drugs R D.; 17 (1): [ADDRESS_1014031] all 
exclusion criteria and prohibited medication ( Table 6 -2). When in doubt the Investigator should 
contact [CONTACT_741681] a new medication to be started. If any of the medications listed in Table [ADDRESS_1014032] be encouraged to continue the follow -up visits even when discontinued permanently from the 
study treatment. 
[COMPANY_001]  Confidential  Page 34 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 Corticosteroids may be administered to participants for SjS clinical disease flares after enrollment into this study as determined necessary by [CONTACT_655034].  
 
: 
• the incremental daily steroid dose is > 2.5 mg/day prednisone or equivalent, or 
• the increased daily steroid dose is administered > 2 days within a 4 -week period.  
6.3 Participant numbering, treatment assignment, randomization  
6.3.1 Participant numbering 
Each participant is identified in the study by a Participant Number (Participant No.) that is assigned when the participant is enrolled into core study, CCFZ533B2201, and is retained for the participant throughout his/her participation in the trial. This b eing an extension study, the 
Participant No. will remain the same as that of the core study; new participant numbers will not be assigned.  
The Participant No. consists of the Centre Number (Centre No.) assigned by [CONTACT_348175] a sequential participant number suffixed to it, so that each participant's participation is numbered uniquely across the entire database. Dur ing the extension study, each 
participant will be uniquely identified by a Participant No..  
6.3.2 Treatment assignment, randomization  
No re -randomization will be performed in this study. At Week 60 of the core study, all eligible 
and consenting participants from the core study will be enrolled via Interactive Response Technology (IRT) and will be re- assigned to one of the treatment arms (refer to Section  6.1.3). 
An IRT algorithm will be programmed to assign the participant to blinded treatment in the extension study using ESSDAI (Cohort 1 and Cohort 2) and ESSPRI (Cohort 2) scores from predefined time points in the TWINSS core study. ESSDAI and ESSPRI scores at predefined time points will be transferred to the extension study IRT database by [CONTACT_741682] ( eCOA ) vendor after the Investigator or his/her delegate has confirmed 
this transfer in the core study (for details, refer to the IRT user guide).  The IRT wil l assign a 
number to the participant, which will be used to link the participant to a treatment arm and will specify a unique medication number for the first package of study treatment to be dispensed to the participant.  
• For participants rolling over from Cohort 1 in the TWINSS core study, the change in ESSDAI score between Week 4 and Week 48 will be used to determine if the participant responded to treatment in the core study. If an ESSDAI score is missing at Week 4 and/or 
Week 48, then Week 0 or Week 40 scores should be respectively used for the algorithm. A 
decrease of 3 points or more from Week 4 (or Week 0 if the ESSDAI score is missing at 
Week 4) will  classify the  participant as a treatment responder in Cohort 1. 
• For participants rolling over from Cohort 2 in the TWINSS core study, a change in both 
ESSDAI and ESSPRI scores between Week 4 and Week 48 will be used to determine if the participant responded to treatment in the core study. If an ESSDAI or ESSPRI score is missing at Week 4 and/or Week 48, then Week 0 or Week 40 scores should be 

[COMPANY_001]  Confidential  Page 35 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 respectively used for the algorithm. A decrease of 1 point or more in both the ESSDAI and ESSPRI scores from Week 4 (or Week 0 if the ESSDAI or ESSPRI score is missing at Week 4) will classify the participant as a treatment responder in Cohort 2. 
6.4 Treatment blinding  
This will be a double -blind treatment until the final database lock of Core study . Participants, 
Investigator, site staff, and persons performing the assessments will remain blinded to the identity of the treatment until the final database lock of the core study, using the following methods: 
1. Treatment assignment data are kept strictly confidential until the time of unblinding and 
will not be accessible by [CONTACT_250345] 
2. The identity of the treatments will be concealed by [CONTACT_131552], schedule of administration and appearance 
The re -assignment codes associated with participants from whom PK samples are taken will 
only be disclosed to the PK bioanalysts who will keep the PK results confidential until primary database lock of the core study (Week 24). Blood samples for PK, immunogenicity and  assessment will be collected for all participants . 
Whenever needed or requested by [CONTACT_6098], before the open -label part of the extension 
study, the bioanalyst will share bioanalytical data in a blinded fashion with the pharmacokineticist.  
Up to final database lock of core study, unblinding will only occur in the case of subject emergencies (see Section  6.6.2).  
After final database lock of core study , the treatment arm for individual participant will be 
unblinded and the study will be conducted open- label.  
Unblinding of the CTT will occur at the time of the primary database lock at Week [ADDRESS_1014033] generated  Treatment 
allocation & dosing  Safety event 
(single participant unblinded)  Primary 
database lock at Week 
[ADDRESS_1014034](s)  B U UI U U 
Global Clinical Supply and 
Randomizatio
n Office  U U U U U 

[COMPANY_001]  Confidential  Page 36 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
   Time or Event    
Role  Treatment re -
assignment 
list generated  Treatment 
allocation & 
dosing  Safety event 
(single 
participant unblinded)  Primary 
database 
lock at Week 
24 of core 
study  Final database 
lock of core study  
Unblinded 
Pharmacovigil
ance sponsor 
staff B UI UI UI U 
Data Monitoring 
Committee 
(DMC)  B U U U U 
CTT and other 
sponsor teams (trial 
team, project 
team, management 
& decision 
boards, 
support 
functions)  B B B U U 
Key: 
UI: Allowed to be unblinded on individual participant level  
U: Unblinded  
B: Remains blinded  
6.5 Dose escalation and dose modification  
Dose escalation is not applicable in this study.  
6.5.1 Dose modifications  
Dose modifications of the investigational drug are not permitted. 
6.5.2 Dose interruptions 
For participants who are not able to follow the protocol -specified dosing schedule due to 
unresolved AEs, or for any other reason cannot attend a visit within a time window specified in 
Section  8, dose interruptions may be occasionally permitted. A maximum of 1 dose  of study 
treatment may be missed in a 3 month period, as specified below. In case of an AE or for any reason (e.g., non- compliance, operational hurdle) resulting in additional interruptions of the 
dosing scheme, consultation and agreement with [COMPANY_001] will be necessary to decide whether the participant can continue or needs to be withdrawn from the treatment.  
Treatment Period  
• No dose interruptions are allowed prior to completion of Week 66 (Day 463): this is a critical period to ensure CD40 occupancy in target tissues  
[COMPANY_001]  Confidential  Page 37 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 • From Week 68 (Day 477) to Week 108 (Day 7 57): [ADDRESS_1014035] be recorded on the appropriate eCRF.  
In all cases the original visit schedule should be maintained (no recalculation from the last visit).  
6.5.[ADDRESS_1014036] once a week (or more frequently if required by [CONTACT_15931], or if clinically indicated) for [ADDRESS_1014037] promote compliance by [CONTACT_297219]'s safety and the validity of the study. The participant must also be i nstructed to contact [CONTACT_121942]/she is unable for any reason to take the study treatment as prescribed. Compliance will be assessed by [CONTACT_11219]/or study personnel at each visit based on information provided by [CONTACT_2299]. This information should be captured in the source document at each visit. All study treatment dispensed and returned must be recorded in the Drug Accountability Log. 
6.6.[ADDRESS_1014038] the participant’s 
next treatment regimen, and after discussion and agreement with the sponsor. Most often, study treatment discontinuation and knowledge of the possible treatment assignments are sufficient to treat a study participant who presents with an emergency condition. Emergency treatment code breaks are performed using the IRT. When the Investigator contacts the system to break a treatment code for a participant, he/she must provide the requested participant identifying information and confirm the necessity to break the treatment code for the participant. The Investigator will then receive details of the investigational drug treatment for the specified 
[COMPANY_001]  Confidential  Page 38 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 participant and a fax or email confirming this information. The system will automatically inform the [COMPANY_001] monitor for the site and the study team that the code has been broken. Participants unblinded following an intentional emergency code breaking should be discontinued from the study. 
It is the Investigator’s responsibility to ensure that there is a dependable procedure in place to 
allow access to the IRT/code break cards at any time in case of emergency. The Investigator will provide: 
• protocol number 
• participant number  
In addition, oral and written information to the participant must be provided on how to contact 
[CONTACT_5657]/her backup in cases of emergency, or when he/she is unavailable, to ensure that un -blinding 
can be performed at any time.  
6.7 Preparation and dispensation  
Each study site will be supplied with study drug CFZ533 (iscalimab) and placebo by [CONTACT_5343], in packaging as described under investigational and control drugs section. 
A unique medication number is printed on the study medication label. Investigator staff will identify the study medication kits to dispense to the participant by 
[CONTACT_105245](s). The study medication has a 2- part 
label (base plus tear -off label), immediately before dispensing the medication kit to the 
participant, site personnel will detach the outer part of the label from the packaging and affix it to the source document. 
As per Section 4.6, during a Public Health emergency as declared by [CONTACT_6620] i.e. pandemic, epi[INVESTIGATOR_6519], that limits or prevents on -site study visits, 
delivery of IMP directly to a participant’s home may be permitted (if allowed by [CONTACT_741683] l or 
Regional Health Authorities and Ethics Committees as appropriate) in the event the Investigator has decided that an on- site visit by [CONTACT_348178], and that 
it is in the interest of the participant’s health to administer the study treatment even without performing an on- site visit. The dispatch of IMP from the site to the participant’s home remains 
under the accountability of the Investigator. Each shipment/provisioning will be for a maximum of 3- month’s supply. In this case, regular phone calls or virtual contacts (every 4 weeks  or more 
frequently if needed) will occur between the site and the participant for instructional purposes, safety monitoring, drug accountability, investigation of any adverse events, ensuring participants continue to benefit from treatment and discussion of the participant´s health status until the participants can resume visits at the study site.  
6.7.1 Handling of study treatment and additional treatment  
[IP_ADDRESS] Handling of study treatment  
Study treatment must be received by a designated person at the study site, handled and stored safely and properly and kept in a secured location to which only the Investigator and designated site personnel have access. Upon receipt, all study treatment must be stored according to the 
[COMPANY_001]  Confidential  Page 39 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 instructions specified on the labels and in the IB. Clinical supplies are to be dispensed only in accordance with the protocol. The Investigator should educate the participant on how to properly store the study treatment if the participant is self- administering at home. Technical 
complaints are to be reported to the respective [COMPANY_001] Country Organization (CO) Quality Assurance.  
The investigational drug iscalimab will be provided in PFS of 300 mg/2mL as a solution for s.c. administration. The matching placebo will be provided in PFS of 0 mg/2 mL as a solution for s.c. administration. Two injections of 2 mL each will be administered to the participant at every dosing visit, as follows:  
Loading regimen:  
CFZ533 (iscalimab) [ADDRESS_1014039] 3 doses (Weeks 60E1, 61 and 62); then, from Week 64, iscalimab will be administered s.c. bi -weekly 
(every other week or Q2W) as described below.  
Maintenance regimen:  
• Arm 1 (iscalimab 600 mg): two 2 mL syringes, each containing 300 mg of iscalimab 
• Arm 2 (iscalimab 300 mg): one [ADDRESS_1014040] that will be conducted 
at selected countries/sites. The digital box allows to capture the real time date and image of the disposal of the syringe. The connected device/box reminds  the participant when medication is 
due, tracks when medication is t aken and interventions as per the [COMPANY_001] trial protocols. 
Detailed instructions on use and handling will be described in a separate manual. For the study participants using the Digital Injection Care Management device, there are no risks associated with the disposal of used syringes after home use in the Smart Sharps bin and/or return of the 
Smart Sharps bin with the used syringes after home use to the study site.   
At the conclusion of the study, and as appropriate during the course of the study, the Investigator will return all unused study treatment, packaging, drug labels, and a copy of the completed drug accountability log to the [COMPANY_001] monitor or to the [COMPANY_001] address provided in the Investigator folder at each site.  
[COMPANY_001]  Confidential  Page 40 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 [IP_ADDRESS] Handling of additional treatment  
Not applicable. 
6.7.2 Instruction for prescribing and taking study treatment  
All kits of study treatment assigned by [CONTACT_6607].  
Study treatment (iscalimab 600 mg and 300 mg) will be administered s.c. by [CONTACT_2299], 
caregiver or site staff. The PFS will be provided by [CONTACT_741684], who will self-administer the injections at the specified study time point. Participants will be instructed in 
detail how to self -administer the s.c. injection using the PFS. Site staff will administer the 
injection to those participants who are not able or unwilling to self -administer the PFS injection. 
Detailed instructions on the self -administration of the study treatment will be described in the 
IFU and provided to each participant. It shall be recorded on the corresponding eCRF(s) whether the participant self- administered the PFS or whether site staff or caregiver administered 
the PFS and whether it was administered at home or at the site.  
Iscalimab 600 mg s.c. Q2W 
• Iscalimab loading doses will be 600 mg s.c. (2 injections of 300 mg/2 mL) on Week 60E1 
(Day 421),  Week 61 (Day 428) and Week 62 (Day 435) 
• From Week 62 the participant will receive 600 mg s.c. Q2W iscalimab until Week 106 (last dose)  
Iscalimab 300 mg s.c. Q2W 
• Iscalimab loading doses will be 600 mg s.c. (2 injections of 300 mg/2 mL) on Week 60E1 
(Day 421), 300 mg s.c. (1 injection of 300mg/2 mL and 1 injection of 2 mL of the placebo) on Week 61 (Day 428) and 300 mg s.c. Week 62 (Day 435) 
• From Week 62 the participant will receive 300 mg s.c. Q2W iscalimab until Week 106 (last dose)  
The first study treatment administration will occur at Week 60E1  after the inclusion/exclusion 
criteria have been confirmed, all study scheduled assessments have been performed and the scheduled blood samples have been drawn. For the loading doses on Week 60E1 (Day 421), Week 61 (Day 428) and Week 62 (Day 435), all injections will be self -administered by [CONTACT_741685] a site staff member after the study assessments for the visit have been completed. Participants will be required to attend the study 
site for the Week 64 visit and starting at Week 66, the participants will be allowed to self -
administer the study medication at home on an alternating basis through to Week 106 or continue to present at the study site for injection administrations, based on the participant's preference and the investigator's judgment. 
The trial- related safety and efficacy procedures will be conducted as indicated in Table [ADDRESS_1014041] been col lected.  
For each study visit at the site, all study assessments including completion of Patient Reported Outcomes (PROs) should be completed prior to the self- administration of the study treatment.  
[COMPANY_001]  Confidential  Page 41 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 All dosages prescribed and dispensed to the participants and all dose changes during the study must be recorded on the Dosage Administration Record CRF. Immediately before dispensing the package to the participant, site staff will detach the outer part of the label from the packaging and affix it to the source document (Drug Label Form) for that participant's unique participant number. 
The investigator should promote compliance by [CONTACT_297219]'s safety and the validity of the study. The participant should be instructed to contact [CONTACT_18611]/she is unable for any reason to take the study treatment as prescribed.  
Administration  
Single syringes will be packed in individual boxes. The site and participant should refer to the IFU for storage and handling instructions. Each injection should be administered into an appropriate injection site of the body (thighs, arms, or abdomen). Each new injection should be administered at the same site on opposite sides of the body or given on two different body sites. If the participant chooses the abdomen, a 2- inch area around the navel should be avoided. 
Investigational drug should not be injected into areas where the skin is tender, bruised, red, or hard or where participant has scars or stretch marks. Injection sites should be alternated to reduce the risk of reaction. Used safety syringes should be disposed immediately after use in a sharps container or according to the regulatory needs to the respective countries.  
Home administration  
Participants (or caregivers) will be allowed to self- administer the PFS at home when they are 
not visiting the site for any other trial- related procedures. Participants will be allowed to self-
administer the PFS at home (starting at Week 66) only if they have exhibited correct use for 
self-administering the PFS at the site during the first [ADDRESS_1014042] been included in the assessment table between the visits at which trial- related procedures are not to be conducted at the site. 
Participants will be allowed to self- administer the PFS at home or to visit the site during the 
optional visits to self- administer the PFS under the supervision of the site staff. If the participant 
is not able or not confident to self -administer the PFS, he/she should visit the site at every 
optional site visit (e.g., every 4 weeks) during the treatment period and the site staff will administer the PFS.  
Prior to self -administration at home, participants should contact [CONTACT_093]/site staff in the 
case they are experiencing any AE/SAEs or have any concerns or there have been changes to the ongoing concomitant medications. 
7 Informed consent procedures  
The following informed consents are included in this study:  
1. Main study consent, which also includes a subsection that requires a separate signature [CONTACT_741694].   
[COMPANY_001]  Confidential  Page 42 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 2. As applicable, Pregnancy Outcomes Reporting Consent for female subjects who took study treatment.   
Eligible participants may only be included in the study after providing (witnessed, where required by [CONTACT_6617]), IRB/IEC -approved informed consent. 
If applicable, in cases where the participant's representative(s) gives consent (if allowed according to local requirements), the participant must be informed about the study to the extent 
possible given his/her understanding. If the participant  is capable of doing so, he/she must 
indicate agreement by [CONTACT_30803]. 
Informed consent must be obtained before conducting any study- specific procedures (e.g. all of 
the procedures described in the protocol). The process of obtaining informed consent must be 
documented in the participant source documents.  
[COMPANY_001]  will provide to investigators in a separate document a proposed informed consent form 
that complies with the ICH GCP guidelines and regulatory requirements and is considered appropriate for this study. Any changes to the proposed consent form suggested by [CONTACT_741686]/IEC.  
Information about common side effects already known about the investigational drug can be found in the IB. This information will be included in the participant  informed consent and 
should be discussed with the participant  during the study as needed. Any new information 
regarding the safety profile of the investigational drug that is identified between IB updates will be communicated as appropriate, for example, via an investigator notification or an aggregate safety finding. New information might require an  update to the informed consent and then must 
be discussed with the participant. 
Women of child bearing potential must be informed that taking the study treatment may involve 
unknown risks to the fetus if pregnancy were to occur during the study and agree that in order 
to participate in the study they must adhere to the contraception r equirements.  
  
 
   
 
  
 
A copy of the approved version of all consent forms must be provided to [COMPANY_001]  after IRB/IEC 
approval. 
Participants might be asked to complete an optional questionnaire to provide feedback on their 
clinical trial experience.  

[COMPANY_001]  Confidential  Page 43 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 8 Visit schedule and assessments 
The Assessment Schedule ( Table 8 -1) lists all of the assessments when they are performed. All 
data obtained from these assessments must be supported in the participant’s source documentation. 
Participants should be seen for all visits/assessments as outlined in the assessment schedule 
(Table 8 -1) or as close to the designated day/time as possible.  
Every efforts should be made to adhere to the weekly dosing schedule (loading doses) and the bi-weekly maintenance dosing regimen in both arms in this trial.  
Visits can be performed with the following time windows: 
Treatment Period  
• +/- 1 calendar day: from Week 60E1 (Day 421) to  Week 61 (Day 428) 
• +/- 2 calendar days: from Week 62 (Day 435) to Week 66 (Day 463) 
• +/- 5 calendar days: from Week 68 (Day 477) to Week 108 (Day 757) 
Follow- up Period  
+/- 5 calendar days from Week 112 (Day 785) to Week 120 (Day 841) 
Note: All efforts need to be made to maintain the actual duration of [ADDRESS_1014043] should be reconciled, and the adverse event and concomitant medications recorded on the CRF.  
As per Section 4.6, during a Public Health emergency as declared by [CONTACT_6620] i.e. pandemic, epi[INVESTIGATOR_157046] -site study visits, 
alternative methods of providing continuing care may be implemented by [CONTACT_6623]. If allowed by [CONTACT_324411], phone calls, virtual contacts (e.g. tele consult) or visits by [CONTACT_6624]/ home nursing staff to the participant´s home, can replace on -site study visits, for the duration of the disruption 
until it is safe for the participant to visit the site again.  
[COMPANY_001]  Confidential  Page 44 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 Table 8-1 Assessment Schedule 
Period  Extension -Treatment  
Visit Name  [CONTACT_22141] 
60E11 Wk 
61 Wk 
62 Wk 
64 Wk 
66 Wk 
68 Wk 
70 Wk 
72 Wk 
74 Wk 
76 Wk 
78 Wk 
80 Wk 
82 Wk 
84 Wk 
86 Wk 
88 Wk 
90 Wk 
92 Wk 
94 Wk 
96 
Days  421 428 435 449 463 477 491 505 519 533 547 561 575 589 603 617 631 645 659 673 
Weeks  60 61 62 64 66 68 70 72 74 76 78 80 82 84 86 88 90 92 94 96 
Optional site visit2         X   X   X   X   X   X   X   X   
Informed consent  X3                                       
Inclusion / Exclusion 
criteria  X                                       
Contact [CONTACT_12067]  X4 X X X   X   X   X   X   X   X   X   X 
Study drug 
administration  X X X X X X X X X X X X X X X X X X X X 
Demography  X                                       
Smoking history  X                                       
Medical history/current 
medical conditions  X                                       
Prior therapy for 
Sjögren's Syndrome  X                                       
Adverse Events5 X X X X X X X X X X X X X X X X X X X X 
Concomitant 
medications  X X X X X X X X X X X X X X X X X X X X 
Physical Examination  C6     S7   S7   S7   S7   S7   S7   S7   S7   S7 
Vital signs and body 
measurements  C6 X X X   X   X   X   X   X   X   X   X 
Electrocardiogram 
(ECG)  X                                       
Hepatitis and CMV 
monitoring (local)9 C6             S7           S7           S7 

[COMPANY_001]  Confidential  Page 45 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 Period  Extension -Treatment  
Visit Name  [CONTACT_22141] 
60E11 Wk 
61 Wk 
62 Wk 
64 Wk 
66 Wk 
68 Wk 
70 Wk 
72 Wk 
74 Wk 
76 Wk 
78 Wk 
80 Wk 
82 Wk 
84 Wk 
86 Wk 
88 Wk 
90 Wk 
92 Wk 
94 Wk 
96 
Days  421 428 435 449 463 477 491 505 519 533 547 561 575 589 603 617 631 645 659 673 
Weeks  60 61 62 64 66 68 70 72 74 76 78 80 82 84 86 88 90 92 94 96 
Hematology  C6     X   X   X   X   X   X   X   X   X 
Clinical Chemistry  C6     X   X   X   X   X   X   X   X   X 
Coagulation Panel10 X             X           X           X 
Immunology  C6         X       X       X       X     
Cryoglobulins11 C6             X           X           X 
Pregnancy test12 C6     X   X   X   X   X   X   X   X   X 
PK blood collection13 C6                 X               X     
Immunogenicity13 C6                 X               X     
Urinalysis dipstick  C6     X   X   X   X   X   X   X   X   X 
Prefilled syringe 
questionnaire16                                         
Trial feedback 
questionnaire16                                         

[COMPANY_001]  Confidential  Page 46 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
  
Period  Extension -Treatment  Post -Treatment Follow -Up 
Visit Name  [CONTACT_22141] 98  Wk 100  Wk 102  Wk 104  Wk 106  Wk 108/TD19 Wk 112  Wk 120/EOS20 
Days  687 701 715 729 743 757 785 841 
Weeks  98 100 102 104 106 108 112 120 
Optional site visit2 X   X   X       
Informed consent                  
Inclusion / Exclusion criteria                  
Contact [CONTACT_12067]    X   X         
Study drug administration  X X X X X21       
Demography                  
Smoking history                  
Medical history/current medical 
conditions                  
Prior therapy for Sjögren's 
Syndrome                  
Adverse Events5 X X X X X X X X 
Concomitant medications  X X X X X X X X 
Physical Examination    S7   S7   S7 S7 S7 
Vital signs and body measurements    X   X   X X X 
Electrocardiogram (ECG)            X     
Hepatitis and CMV monitoring 
(local)9           S7   S7 
Hematology    X   X   X X X 
Clinical Chemistry    X   X   X X X 
Coagulation Panel10           X     
Immunology    X       X X X 
Cryoglobulins11           X   X 
Pregnancy test12   X   X   X X X 

[COMPANY_001]  Confidential  Page 47 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 Period  Extension -Treatment  Post -Treatment Follow -Up 
Visit Name  [CONTACT_22141] 98  Wk 100  Wk 102  Wk 104  Wk 106  Wk 108/TD19 Wk 112  Wk 120/EOS20 
Days  687 701 715 729 743 757 785 841 
Weeks  98 100 102 104 106 108 112 120 
PK blood collection13           X   X 
Immunogenicity13           X   X 
Urinalysis dipstick    X   X   X X X 
Prefilled syringe questionnaire16           X     
Trial feedback questionnaire16               X 

[COMPANY_001]  Confidential  Page 48 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 Period  Extension -Treatment  Post -Treatment Follow -Up 
Visit Name  [CONTACT_22141] 98  Wk 100  Wk 102  Wk 104  Wk 106  Wk 108/TD19 Wk 112  Wk 120/EOS20 
Days  [ADDRESS_1014044] IRT for new treatment reassignment.  
5 AEs/SAEs occurring after the participant has signed the informed consent must be captured on the appropriate eCRF page.  
6 C - These assessments shall be conducted as part of the core study CCFZ533B2201 and will not be repeated in this extension study  
7 S - Assessment to be recorded in the source documentation only  
8 . 
9 Local lab testing of CMV IgG, IgM and DNA (by [CONTACT_954]) must be performed every 3 months until end of study. Hepatitis B monitoring applicable to HBsAg ( -) patients 
who were HBcAb (+) and HBV DNA ( -) at screening during the core study. Local lab testing of HBsAg and HBV DNA must be performed every [ADDRESS_1014045] antiphospholipid antibodies (lupus anticoagulant, anti -cardiolipin antibodies) and/or 
who are on pre -existing antithrombotic therapy/prophylaxis, as reflected in the exclusion criteria of the TWINSS core study protocol.  
[ADDRESS_1014046] dose administration visit in the Tr eatment Period.  

[COMPANY_001]  Confidential  Page 49 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 8.1 Screening  
Not applicable for this extension study. 
8.1.1 Information to be collected on screening failures  
Not applicable for this extension study. 
8.2 Participant demographics/other baseline characteristics  
Country- specific regulations should be considered for the collection of demographic and 
baseline characteristics in alignment with eCRF.  
Participant demographic and baseline characteristic data to be collected on all participants 
include: age, sex, race, ethnicity, smoking history, relevant medical history/current medical condition present before signing informed consent where possible, dia gnoses instead of 
symptoms will be recorded.  
Investigators will have the discretion to record abnormal test findings on the medical history eCRF if, in their judgment, the test abnormality occurred prior to the informed consent signature.  
  
 
 
  
 
 
 
 
  
   
  
      

[COMPANY_001]  Confidential  Page 50 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
  
 
 
  
 
  
    
 
 
  
    
 
  
   
 
    
 
  
    
 
8.4 Safety  
Safety assessments are specified below with the assessment schedule detailing when each assessment is to be performed.  

[COMPANY_001]  Confidential  Page 51 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 As per Section 4.6, during a Public Health emergency as declared by [CONTACT_6586] i.e. pandemic, epi[INVESTIGATOR_6519], that limits or prevents on -site study visits, 
regular phone or virtual calls can occur ( every 4 weeks or  more frequently if needed) for safety 
monitoring and discussion of the participant´s health status until it is safe for the participant to visit the site again.  
For details on AE collection and reporting, refer to Section  10. 
Table 8-2 Assessment and Specifications 
Assessment  Specification  
Physical 
examination  A complete physical examination will include the examination of general 
appearance, skin, neck (including thyroid), eyes, ears, nose, throat, lungs, 
heart, abdomen, back, lymph nodes, extremities, vascular, and neurological. 
If indicated based on medical history and/or symptoms, rectal, external 
genitalia, breast, and/or pelvic exams may be performed.  
A short physical exam will include the examination of general appearance 
and vital signs (blood pressure and pulse). A short physical exam will be at all 
visits where ESSDAI assessments are not required.  
The Investigator should ask the participant for and pay attention to presence of signs and symptoms of infection.  
Information for all physical examinations must be included in the source 
documentation at the study site. Clinically relevant findings that are present prior to signing informed consent must be recorded on the appropriate CRF 
that captures medical history.  Significant findings made after signing informed 
consent which meet the definition of an Adverse Event must be recorded as 
an adverse event.  
Vital signs  If possible, vital sign assessments should be performed by [CONTACT_741687]. Vital 
signs include blood pressure (BP) and pulse measurements. After the participant has been sitting for five minutes, with back supported and both 
feet placed on the floor, systolic and diastolic blood pressure will be 
measured three times using an automated validated device, with an 
appropriately sized cuff.  
Clinically notable vital signs are defined in Section  16.1. 
Body measurements  Height in centimeters (cm) and body weight (to the nearest 0.1 kilogram (kg) 
in indoor clothing, but without shoes) will be measured as specified in Table 
8-1
. 
Body mass index (BMI) will be calculated using the following formula: BMI = 
Body weight (kg) / [Height (m)][ADDRESS_1014047] be reported and discussed with [COMPANY_001] personnel. The results should be evaluated for criteria defining an AE and reported as such if the criteria are met. Repeated evaluations are mandatory until normalization of the result(s) or until the change is no longer clinically relevant. In case of doubt, [COMPANY_001] personnel should again be contact[INVESTIGATOR_530]. 
[COMPANY_001]  Confidential  Page 52 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 In all cases, the Investigator must document in the source documents, the clinical considerations (i.e. result was/was not clinically significant and/or medically relevant) in allowing or disallowing the participant to continue in the study. 
Clinically significant abnormalities must be recorded as either medical history/current medical 
conditions or adverse events as appropriate. All listed below laboratory evaluations will be performed by a central laboratory with exception of erythrocyte sed imentation rate (ESR), 
urinalysis, urine pregnancy test, cryoglobulins and hepatitis monitoring (HBsAg and HBV -
DNA) applicable to HBsAg -negative, anti -HBc positive participants continuing from the 
TWINSS core study and CMV monitoring. 
Table 8-[ADDRESS_1014048] Name  
[CONTACT_6675], Hemoglobin, Platelets, Red blood cells, White blood cells, Differential (Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, 
Bands, Other), Erythrocyte sedimentation rate (ESR - local testing)  
Chemistry  Albumin, Alkaline phosphatase, Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Gamma- glutamyl - transferase (GGT), Lactate 
dehydrogenase (LDH), Bicarbonate, Calcium, Magnesium, Phosphorus, Chloride, Sodium, Potassium, Creatinine, Direct Bi lirubin, Indirect Bilirubin, 
Total Bilirubin, Total Cholesterol, Low Density Lipoprotein (LDL), High 
Density Lipoprotein (HDL), Total Protein, Triglycerides, Blood Urea Nitrogen 
(BUN) or Urea, Uric Acid, Amylase, Lipase, Glucose (non -fasting), C -reactive 
protein (CRP). Estimated creatinine clearance will be calculated using MDRD 
formula.  
Urinalysis (locally)  Macroscopic Panel: (Dipstick)  
pH, Glucose, Protein, Blood, Bilirubin, Urobilinogen, Ketones, Urine nitrite, 
Leukocytes, Specific Gravity.  
If the dipstick result is positive for protein, nitrite, leucocytes and/ or blood, the 
sample will be analyzed locally for culture and for microscopic analysis of 
white blood cells, red blood cells and casts.  
Coagulation  Prothrombin time (PT), Partial Thromboplastin Time (PTT), International 
normalized ratio (INR)  
Immunology   Complement (C3, C4)  
CMV, Hepatitis 
monitoring (locally, 
as applicable)  HBsAg, HBV -DNA, CMV serology (CMV IgG, IgM) and CMV DNA by [CONTACT_741688]  (local testing), PK, PD ( ) and immunogenicity 
(anti-CFZ533 anti -bodies) blood samplings,  
Pregnancy Test  Urine pregnancy test (please see Section  8.4.3 ) 
8.4.2 Electrocardiogram (ECG)  
Electrocardiograms (ECGs) must be recorded after [ADDRESS_1014049], followed by [CONTACT_18651], and blood sampling, and then all other assessments. The Fridericia QT correction formula (QTcF) should be used for clinical decis ions. 

[COMPANY_001]  Confidential  Page 53 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 Single [ADDRESS_1014050] be redacted (e.g., participant initials, date of birth). Results must be entered into the eCRF.  
For any ECGs with participant safety concerns (e.g., severe arrhythmia, conduction abnormality of QTcF > 500 ms), two additional ECGs must be performed to confirm the safety finding. If the participant is hemodynamically compromised, the investigator or a medically qualified person must initiate appropriate safety procedures without delay (for example cardioversion).  
Clinically significant abnormalities must be recorded on the CRF as either medical history/current medical conditions or adverse events as appropriate.  
8.4.[ADDRESS_1014051] (serum pregnancy test). If positive, 
the participant  must be discontinued from the study treatment. Highly effective method of birth 
control must be used for women of childbearing potential (see exclusion criteria definitions, Section  5.2). In consideration of the patient population and overall iscalimab risk benefit 
profile, women of child -bearing potential must utilize highly effective contraception methods 
to avoid becoming pregnant while receiving iscalimab and for [ADDRESS_1014052] dose is justified 
based on predicted PK profiles at 10 mg/kg, where isca limab is predicted to be fully cleared 
from plasma and tissues, with no residual pharmacodynamic activity.  
If participants cannot visit the site to have pregnancy tests, urine pregnancy test kits may be 
used. Relevant participants can perform the urine pregnancy test at home and report the result to the site. It is important that participants are instructed to perform the urine pregnancy test 
first, and only if the test result is negative are they to proceed with administration of the study 
treatment. A communication process should be established with the participant so that the s ite 
is informed and can verify the pregnancy test results (e.g. , following country- specific 
measures) . 
8.4.4 Other safety evaluations  
Malignancies  
For participants on study treatment and in follow -up, any type of malignancies (including skin 
neoplasms, leukemia, post -transplantation proliferative disorder (PTLD)) should be reported as 
an SAE and recorded on the appropriate eCRFs. An SAE report should be completed for malignancies occurring until the last visit (for participants in follow -up) o r for [ADDRESS_1014053] dose of study treatment taken (for participants in the treatment period or who completed the treatment period).  
 
[COMPANY_001]  Confidential  Page 54 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 Infections  
Infections should be recorded with start and end date, type of infection, and medications used on the appropriate eCRFs. If medications are used to treat the infection, the name [CONTACT_741695]. If the participant is hospi[INVESTIGATOR_741663]. 
8.4.[ADDRESS_1014054] for this indication/participant population.  
8.5 Additional assessments 
  
  
 
•
  
 
•  
  
 
 
 
•  
•  
•  
 
 
   
 
    

[COMPANY_001]  Confidential  Page 55 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
      
 
 
   
 
  
T
rial Feedback  
This trial will include an option for participants to complete an anonymized questionnaire, ‘Trial Feedback Questionnaire’ (TFQ) for participants to provide feedback on their experience in a [COMPANY_001] clinical trial. The TFQ is a validated web -based questio nnaire. The TFQ has been 
tested and validated by [CONTACT_741689], PatientsLikeMe and HRM using established PRO methodology and is based on feedback from [ADDRESS_1014055] data about the participant's disease, symptoms, treatment effect or adverse events and therefore the TFQ data is not trial data.  
The TFQ data will be stored in the eCOA vendor provider database, separate from the clinical trial database.  
Satisfaction with self -injection using a prefilled syringe questionnaire (PFS 
Questionnaire)  
This trial will include an option for participants self- administering CFZ533 (iscalimab) or 
placebo with PFS outside of clinic to complete a study- specific questionnaire to evaluate their 
experience and satisfaction with using the PFS ( Section  16.10). Feedback is anonymous. 
Individual participant level responses will not be reviewed by [CONTACT_4718] . 
The questionnaire consists of five questions and measures the confidence, ease of use, convenience, satisfaction and the participant's willingness to self -inject. Each question has five 
answers from “1 = not easy/not confident/not convenient/not satisfied/ definitely not” to “5 = 

[COMPANY_001]  Confidential  Page 56 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 very easy/very confident/very convenient/very satisfied/yes definitely”. The scores will be reported per question and no overall score will be calculated. Higher scores mean higher satisfaction, better experience. The questionnaire will be available in eac h language for each 
country participating in this study following a validated translation process. 
The optional questionnaire will be completed at the site at Week 108, end of the treatment 
period. 
Site and participants will receive clear instructions on the completion of the questionnaire. Site 
must allow participants to complete the questionnaire on  their own without any assistance from 
the site staff.  
The PFS data will be stored in the eCOA vendor database, separate from the clinical trial database.  
8.5.2 Pharmacokinetics 
Free CFZ533 (iscalimab) plasma concentrations will be measured in all participants.  
PK samples will be collected at the visits defined in the assessment schedule. All blood samples will be taken by [CONTACT_677467] a forearm vein. Details of sample processing, handling, storage and shipment w ill be described in a separate 
laboratory manual.  
All samples will be given a unique sample number and a dose reference identification number as listed in the Section  16.5. The actual sample collection date and time will be entered on the 
appropriate eCRF.  
Free CFZ533 (iscalimab) plasma concentrations will be determined using a validated target -
based sandwich assay. The data and details of the analytical methods will be provided in a standalone Bioanalytical Data Report. 
Concentrations below the lower limit of quantification (LLOQ) will be reported as “zero” and 
missing data will be labeled as such in the Bioanalytical Data Report.  
For each PK sample, the actual recorded sampling time will be captured, and the elapsed time since the first and since the last dose will be calculated.  
8.5.3 Immunogenicity  
The presence of anti -CFZ533 (iscalimab) antibodies will be determined in all participants, using 
a validated assay.   
All blood samples will be taken by [CONTACT_677467] a forearm vein. Details of sample processing, handling, storage and shipment will be described in a separate laboratory manual.  
All samples will be given a unique sample number as listed in the Section  16.5. The data and 
details of the analytical methods will be provided in a standalone Bioanalytical Data Report. 
[COMPANY_001]  Confidential  Page 57 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
   
   
 
 
 
 
 
 
 
 
 
 
  
  
 
 
. 
  
  
 
         

[COMPANY_001]  Confidential  Page 58 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
   
      
  
[ADDRESS_1014056] discontinue study treatment for a given participant if, he/she believes that 
continuation would negatively impact the participant's well -being. 
Study treatment must be discontinued under the following circumstances: 
• Participant/guardian decision  
• Pregnancy 
• Use of prohibited treatment as per recommendations in the prohibited treatment section  
• Any situation in which study participation might result in a safety risk to the participant 
• Following emergency unblinding of the treatment arm 
• Emergence of the following adverse events:  
• Persistent neutropenia Common Terminology Criteria (CTC) grade 3 or higher  
• SAEs or severe AEs of infection  
• Any laboratory abnormalities that in the judgment of the investigator, taking into 
consideration the participant’s overall status, prevents the participant from continuing participation in the study  
If discontinuation of study treatment occurs, the investigator should make a reasonable effort to understand the primary reason for the participant’s premature discontinuation of study treatment and record this information.  
Participants who discontinue study treatment or who decide they do not wish to participate in the study further should NOT be considered withdrawn from the study UNLESS they withdraw their consent (see 'Withdrawal of Informed Consent' section). Where possible, they should return for the follow -up assessments indicated in the Assessment Schedule. If they fail to 
return for these assessments for unknown reasons, every effort (e.g., telephone, e -mail, letter) 

[COMPANY_001]  Confidential  Page 59 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 should be made to contact [CONTACT_2299]/pre -designated contact [CONTACT_402799] -up section. This contact [CONTACT_6636].  
If the participant cannot or is unwilling to attend any visit(s), the site staff should maintain regular telephone contact [CONTACT_6635], or with a person pre -designated by [CONTACT_2416]. This telephone contact [CONTACT_6636].  
After study treatment discontinuation, at a minimum, in abbreviated visits, the following data should be collected at clinic visits or via telephone/email contact:  
• New / concomitant treatments  
• Adverse Events / Serious Adverse Events  
The investigator must also contact [CONTACT_6637]’s discontinuation from study treatment. 
If discontinuation occurs because treatment code has been broken, please refer to Emergency 
breaking of treatment code section ( Section  6.6.2).  
[IP_ADDRESS] Replacement policy  
Participants who are prematurely withdrawn or discontinued from the study will not be replaced.  
9.1.2 Withdrawal of informed consent  
Participants may voluntarily withdraw consent to participate in the study for any reason at any time. Withdrawal of consent occurs only when a participant: 
• Does not want to participate in the study anymore, and 
• Does not want any further visits or assessments, and  
• Does not want any further study related contacts 
In this situation, the investigator should make a reasonable effort (e.g., telephone, e -mail, letter) 
to understand the primary reason for the participant’s decision to withdraw his/her consent and 
record this information.  
Where consent to the use of personal and coded data is not required, participant therefore cannot withdraw consent. They still retain the right to object to the further use of personal data.  
Study treatment must be discontinued and no further assessments conducted, and the data that would have been collected at subsequent visits will be considered missing.  
Further attempts to contact [CONTACT_6639] -up. 
All efforts should be made to complete the assessments prior to study discontinuation. A final evaluation at the time of the participant’s study discontinuation should be made as detailed in the assessment table.  
[COMPANY_001]  will continue to retain and use all research results (data) that have already been 
collected for the study evaluation.  
[COMPANY_001]  Confidential  Page 60 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 9.1.[ADDRESS_1014057] show "due diligence" by [CONTACT_6638], e.g., dates of telephone calls, registered letters, etc. A participant should not be considered as lost to follow -
up until due diligence has been completed or until the time point of his/her last study visit has passed . 
9.1.4 Early study termination by [CONTACT_201078]. This may include reasons related to the benefit/risk assessment of participating in the study, practical reasons (including slow enrollment), or for regulatory or medical reasons. In takin g the decision to terminate, 
[COMPANY_001] will always consider the subject welfare and safety. Should early termination be necessary, subjects must be seen as soon as possible and treated as a prematurely withdrawn subject. The investigator may be informed of additional procedures to be followed in order to 
ensure that adequate consideration is given to the protection of the subject’s interests. The investigator or sponsor depending on the local regulation will be responsible for informing IRBs/IECs of the early termination of the trial.  
9.[ADDRESS_1014058] participant finishes their Study Completion visit (all visits until Week 120 visit) and any repeat assessments associated with this visit have been documented and followed- up appropriately by [CONTACT_29517], in the event of an early study 
termination decision, the date of that decision. The final analysis of the study will be performed at the end of the study (EOS). The EOS is defined when all re -assigned participants have 
completed Week [ADDRESS_1014059] refer them for appropriate ongoing care. This care may 
include another treatment outside of the study as deemed appropriate by [CONTACT_093]. 
10 Safety monitoring and reporting  
10.1 Definition of adverse events and reporting requirements  
10.1.1 Adverse events 
An adverse event (AE) is any untoward medical occurrence (e.g., any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a subject or clinical investigation subject after providing written informed consent for pa rticipation in the 
study. Therefore, an AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product.  
The investigator has the responsibility for managing the safety of individual subject and identifying adverse events. 
[COMPANY_001]  Confidential  Page 61 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 [COMPANY_001] qualified medical personnel will be readily available to advise on trial related medical questions or problems.  
In addition, all reports of intentional misuse and abuse of the product are also considered an adverse event irrespective if a clinical event has occurred.  
The occurrence of adverse events must be sought by [CONTACT_105]- directive questioning of the subject at 
each visit during the study. Adverse events also may be detected when they are volunteered by [CONTACT_109049], laboratory test findings, or other assessments. 
Abnormal laboratory values or test results constitute adverse events only if they fulfill at least 
one of the following criteria:  
• they induce clinical signs or symptoms,  
• they are considered clinically significant,  
• they require therapy.  
Clinically significant abnormal laboratory values or test results must be identified through a review of values outside of normal ranges/clinically notable ranges, significant changes from baseline or the previous visit, or values, which are considered non- typi[INVESTIGATOR_279832]. Investigators have the responsibility for managing the safety of individual subject and identifying adverse events. Alert ranges for laboratory and other test abnormalities are included in Section  16.1. 
Adverse events must be recorded under the signs, symptoms, or diagnosis associated with them, accompanied by [CONTACT_6644] (as far as possible) (if the event is serious refer to Section  10.1.2):  
1. The severity grade  
• mild: usually transient in nature and generally not interfering with normal activities  
• moderate: sufficiently discomforting to interfere with normal activities  
• severe: prevents normal activities  
2. its relationship to the study treatment (Yes/ No)  
3. its duration (start and end dates) or if the event is ongoing, an outcome of not 
recovered/not resolved must be reported  
4. whether it constitutes a SAE (see Section  10.1.2 for definition of SAE) and which 
seriousness criteria have been met  
5. action taken regarding with study treatment  
All adverse events must be treated appropriately. Action taken with the study medication 
must be recorded. It may include one or more of the following: 
• Dose not changed 
• Dose Reduced/increased  
• Drug interrupted/withdrawn  
6. Its outcome 
• not recovered/not resolved; 
• recovered/resolved; 
[COMPANY_001]  Confidential  Page 62 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 • recovering/resolving, 
• recovered/resolved with sequelae;  
• condition deteriorated 
• fatal, or unknown. 
Conditions that were already present at the time of informed consent should be recorded in medical history of the subject.  
Adverse events (including lab abnormalities that constitute AEs) should be described using a diagnosis whenever possible, rather than individual underlying signs and symptoms. 
Adverse event monitoring should be continued for at least [ADDRESS_1014060] be followed until its resolution or until it is judged to 
be permanent (e.g. continuing at the end of the study), and assessment must be made at each visit (or more frequently, if necessary) of any changes in seve rity, the suspected relationship to 
the interventions required to treat it, and the outcome.  
Information about adverse drug reactions for the investigational drug can be found in the Investigator's Brochure (IB). This information will be included in the subject informed consent and should be discussed with the subject during the study as needed. Any new information regarding the safety profile of the medicinal product that is identified between IB updates will be communicated as appropriate, for example, via an Investigator Notification or an Aggregate Safety Finding. New information might require an update to the informed consent and has then to be discussed with the subject.  
The investigator must also instruct each subject to report any new adverse event (beyond the 
protocol observation period) that the subject, or the subject’s personal physician, believes might reasonably be related to study treatment. This information must be recorded in the investigator’s source documents; however, if the AE meets the criteria of an SAE, it must be reported to [COMPANY_001].  
10.1.2 Serious adverse events 
An SAE is defined as any adverse event [appearance of (or worsening of any pre -existing)] 
undesirable sign(s), symptom(s), or medical conditions(s) which meets any one of the following criteria:  
• fatal 
• life-threatening  
Life-threatening in the context of an SAE refers to a reaction in which the subject was at risk of 
death at the time of the reaction; it does not refer to a reaction that hypothetically might have caused death if it were more severe (please refer to the IC H-E2D Guidelines). 
• results in persistent or significant disability/incapacity  
• constitutes a congenital anomaly/birth defect 
• requires inpatient hospi[INVESTIGATOR_1081], unless hospi[INVESTIGATOR_062]:  
[COMPANY_001]  Confidential  Page 63 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 • routine treatment or monitoring of the studied indication, not associated with any deterioration in condition 
• elective or pre -planned treatment for a pre-existing condition that is unrelated to the 
indication under study and has not worsened since signing the informed consent (e.g., liver allograft biopsy, hospi[INVESTIGATOR_741664], revision of an incisional hernia, etc..)  
• social reasons and respi[INVESTIGATOR_108999]’s general condition 
• treatment on an emergency outpatient basis for an event not fulfilling any of the definitions of an SAE given above and not resulting in hospi[INVESTIGATOR_063] 
• is medically significant, e.g., defined as an event that jeopardizes the subject or may require medical or surgical intervention to prevent one of the outcomes listed above 
Medical and scientific judgment should be exercised in deciding whether other situations should be considered serious reactions, such as important medical events that might not be immediately life threatening or result in death or hospi[INVESTIGATOR_37208]. Such events should be considered as “medically significant.” Examples of such events are intensive treatment in an emergency room or at home for allerg ic bronchospasm, blood dyscrasias, or convulsions that 
do not result in hospi[INVESTIGATOR_6536] (please refer to the ICH - 
E2D Guidelines). 
All malignant neoplasms will be assessed as serious under “medically significant” if other 
seriousness criteria are not met.  
Any suspected transmission via a medicinal product of an infectious agent is also considered a serious adverse reaction.  
All reports of intentional misuse and abuse of the product are also considered serious adverse event irrespective if a clinical event has occurred.  
10.1.[ADDRESS_1014061] be reported separately as a new event.  
[COMPANY_001]  Confidential  Page 64 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 If the SAE is not previously documented in the Investigator’s Brochure or Package Insert (new occurrence) and is thought to be related to the study treatment, a Chief Medial Office & Patient Safety (CMO & PS) department associate may urgently require further information from the investigator for health authority reporting. [COMPANY_001] may need to issue an Investigator Notification (IN) to inform all investigators involved in any study with the same study treatment that this SAE has been reported. 
Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs) will be collected and reported to 
the competent authorities and relevant ethics committees in accordance with EU Guidance 2011/C 172/01 or as per national regulatory requirements in participating countries.  
Note: SAEs must be reported to [COMPANY_001] within 24 hours of the investigator learning of its occurrence/receiving follow -up information. 
10.1.[ADDRESS_1014062] be 
reported to [COMPANY_001] within 24 hours of learning of its occurrence. The pregnancy should be followed up to determine outcome, including spontaneous or voluntary t ermination, details of 
the birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal and/or newborn complications. 
Pregnancy should be recorded and reported by [CONTACT_37288] (CMO&PS). Pregnancy follow -up should be recorded on the same 
form and should include an assessment of the possible relationship to the study treatment. Any SAE experienced during pregnancy must be reported. Information will be collected at three time points after the estimated date of delivery and for a period of 12 months.  
10.1.5 Reporting of study treatment errors including misuse/abuse  
Medication errors are unintentional errors in the prescribing, dispensing, administration or monitoring of a medicine while under the control of a healthcare professional, subject or consumer (EMA definition). 
Misuse refers to situations where the medicinal product is intentionally and inappropriately used 
not in accordance with the protocol. 
Abuse corresponds to the persistent or sporadic, intentional excessive use of a medicinal 
product, which is accompanied by [CONTACT_3584]. 
Study treatment errors and uses outside of what is foreseen in the protocol will be recorded on 
the appropriate CRF irrespective of whether or not associated with an AE/SAE and reported to Safety only if associated with an SAE. Misuse or abuse will be coll ected and reported in the 
safety database irrespective of it being associated with an AE/SAE within 24 hours of Investigator’s awareness.  
[COMPANY_001]  Confidential  Page 65 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 Table 10-1 Guidance for capturing the study treatment errors including 
misuse/abuse 
Treatment error type  Document in Dosing 
CRF (Yes/No)  Document in AE 
eCRF  Complete SAE form  
Unintentional study 
treatment error  Yes Only if associated with 
an AE  Only if associated with 
an SAE  
Misuse/Abuse  Yes Yes Yes, even if not 
associated with a SAE  
For more information on AE and SAE definition and reporting requirements, please see the 
respective sections.  
10.[ADDRESS_1014063] on the liver (refer to the current Investigator's Brochure). Standard liver function tests (LFT) will be obtained at regular intervals.  
The following two categories of abnormalities / adverse events have to be considered during the course of the study (irrespective of whether classified/reported as (S)AE):  
• Liver laboratory triggers, which will require repeated assessments of the abnormal laboratory parameter  
• Liver events, which will require close observation, follow -up monitoring and completion 
of the standard base liver CRF pages 
Please refer to Section  16.2 for complete definitions of liver laboratory triggers and liver events.  
Every liver laboratory trigger or liver event as defined in Section  16.2 should be followed up 
by [CONTACT_579085]. Detailed information is outlined in Section  16.2. 
For the liver laboratory trigger: 
• Repeating the liver function test (LFT) within the next week to confirm elevation.  
These LFT repeats must be performed using the central laboratory if possible. If this is not 
possible, then the repeats can be performed at a local laboratory to monitor the safety of the patient. Repeats laboratory must then be performed at central labora tory as soon as possible. If 
a liver event is subsequently reported, any local LFTs previously conducted that are associated with this event must be reported on the Liver CRF pages. 
• If the elevation is confirmed, close observation of the patient will be initiated, including 
consideration of treatment interruption if deemed appropriate. 
For the liver events: 
• Repeating the LFT to confirm elevation as appropriate 
• Discontinuation of the investigational drug if appropriate  
• Hospi[INVESTIGATOR_741665] 66 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 • A causality assessment of the liver event via exclusion of alternative causes (e.g., disease, co-medications)  
• An investigation of the liver event which needs to be followed until resolution. 
These investigations can include serology tests, imaging and pathology assessments, hepatologist’s consultancy, based on investigator’s discretion. All follow -up information, and 
the procedures performed must be recorded on appropriate CRF pages, including the liver event 
overview CRF pages. 
10.2.[ADDRESS_1014064] to be considered during the course of the study: 
1. Serum event  
• confirmed (after ≥ 24h) increase in serum creatinine of ≥ 25% compared to baseline 
during normal hydration status 
2. Urine event  
• New dipstick proteinuria ≥3+ OR Protein -creatinine ratio ≥150 mg/g or ≥ 15 mg/mmol 
• New dipstick hematuria ≥3+ on urine dipstick. Every renal laboratory trigger or renal event as defined in Section  16.3 should be followed-up by [CONTACT_741690].  
10.2.3 Data Monitoring Committee  
No separate data monitoring committee (DMC) will be formed for the extension study. The DMC of the core study may review the safety data of this trial at less frequent intervals (i.e., planned every 6 months) until final database lock of the core study. Specific details regarding the DMC process will be available in the core study DMC charter.  
Additional meetings may be scheduled if discussion of any issue is required. 
[ADDRESS_1014065] will be defined in the protocol and the Assessment Schedule ( Table 8 -1) and can be recorded directly on the eCRFs. All other data captured for 
this study will have an external originating source (either written or electronic) with the eCRF not being considered as source. 
Designated investigator staff will enter the data required by [CONTACT_37290] (eCRF). The eCRFs have been built using fully validated secure web-enabled software that conforms to 21 CFR (Code of Federal Regulation) Part 11 requirements, Investigator site staff will not be given access to the Electronic Data Capture (EDC) system until they have been trained. Automatic validation programs check for data discrepancies in the 
[COMPANY_001]  Confidential  Page 67 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 eCRFs. The EDC system allows modification and/or verification of the entered data by [CONTACT_6649].  
The investigator/designee is responsible for assuring that the data (entered into eCRF) is complete, accurate, and that entry and updates are performed in a timely manner. The Investigator must certify that the data entered are complete and accurate.  
After final database lock, the investigator will receive copi[INVESTIGATOR_6540].  
All data should be recorded, handled, and stored in a way that allows its accurate reporting, interpretation, and verification.  
11.2 Database management and quality control  
[COMPANY_001] personnel will review the data entered by [CONTACT_5375]. Electronic data queries stating the nature of the problem and requesting clarification will be created for discrepancies and missing values and sent to the investigational site via the EDC system. Designated investigator site staff are required to respond promptly to queries and to make any necessary changes to the data.  
Concomitant treatments and prior medications entered into the database will be coded using the World Health Organization (WHO) Drug Reference List, which employs the Anatomical Therapeutic Chemical classification system. Medical history/current medical con ditions and 
adverse events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) terminology. 
Re-assignment codes and data about all study treatment(s) dispensed to the participant and all 
dosage changes will be tracked using an Interactive Response Technology (IRT). The system 
will be supplied by a vendor, who will also manage the database. The da ta will be sent 
electronically to [COMPANY_001] at specific timelines.  
Each occurrence of a code break via IRT will be reported to the clinical team and monitor. The code break functionality will remain available until study shut down or upon request of [COMPANY_001].  
Once all the necessary actions have been completed and the database has been declared to be complete and accurate, it will be locked and the treatment codes will be made available for data analysis. Any changes to the database after that time can only be made after written agreement by [CONTACT_188660]. 
11.3 Site monitoring  
Before study initiation, at a site initiation visit or at an investigator’s meeting, a [COMPANY_001] representative will review the protocol and data capture requirements (i.e., eCRFs) with the investigators and their staff. During the study, [COMPANY_001] employs s everal methods of ensuring 
protocol and GCP compliance and the quality/integrity of the sites’ data. The field monitoring will be performed according to relevant sections of the monitoring plan. Blinded monitors will visit the site to check the completenes s and appropriate storage of investigator site files, subject 
records, the accuracy of data capture / data entry, the adherence to the protocol, to the study 
[COMPANY_001]  Confidential  Page 68 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 procedures and to Good Clinical Practice. The monitor is also responsible to report any deviation from the protocol or defined procedures and to follow the progress of enrollment. Monitors are responsible to ensure that study treatment is being stored, dispensed, and accounted for according to specifications. Key study personnel must be available to assist the field monitors during these visits. Continuous remote monitoring of each site’s data may be performed by a centralized [COMPANY_001]/CRA (Clinical Researc h Associate) organization. 
Additionally, a central analytics organization may analyze data and identify risks and trends for site operational parameters, and provide reports to [COMPANY_001] clinical teams to assist with trial oversight. 
The investigator must maintain source documents for each subject in the study, consisting of 
case and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical information, laboratory data, electrocardiograms, and the results of any other tests or assessments. All information on eCRFs must be traceable to these source documents in the subject’s file. The investigator must also keep the original informed consent forms signed by [CONTACT_423] (a signed copy is given to the subject). 
The investigator must give the monitor access to all relevant source documents in paper or 
electronic format to confirm their consistency with the data capture and/or data entry. [COMPANY_001] monitoring standards require full verification for the presence of informed consent, adherence to the inclusion/exclusion criteria, documentation of SAEs, and of data that will be used for all primary variables. Additional checks of the consistency of the source data with the eCRFs are performed according to the study- specific monitoring plan. No information in source 
documents about the identity of the subjects will be disclosed. 
[ADDRESS_1014066] deviation (SD), 
minimum, lower quartile, median, upper quartile, and maximum. Summary statistics for discrete variables will be presented in the number and percent of patients in each category. 
12.1 Analysis sets  
The Full Analysis Set (FAS) comprises all participants to whom study treatment for the extension study has been assigned by [CONTACT_238522] -assignment algorithm. For analysis on FAS, 
participants will be analyzed according to the treatment group to which they have been assigned. Only data in the extension study will be included in the analysis. 
The Safety Set (SAF) includes all participants who received at least one dose of study treatment 
during the extension study. Participants will be analyzed according to the study treatment received, where treatment received is defined as the assigned treatm ent if the participant took 
at least one dose of that treatment or the first treatment received if the assigned treatment was never received. Only data in the extension study will be included in the analysis. 
[COMPANY_001]  Confidential  Page 69 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 12.2 Participant demographics and other baseline characteristics  
Analyses will be based on the FAS.  
Demographics and baseline characteristics:  
Summary statistics will be presented for continuous demographic and baseline characteristic variables from core study for each treatment group. The number and percentage of participants in each category will be presented for categorical variables for each treatment group and all participants.  
Medical history: 
Disease- specific medical history and any condition entered as medical history or current 
medical conditions at core baseline will be coded using the MedDRA dictionary. They will be 
summarized by [CONTACT_741691]. 
12.3 Treatments  
Analyses of treatment will be based on the SAF.  
Study treatment:  
The duration of exposure to study treatment will be summarized by [CONTACT_1570]. In addition, the number of participants with exposure of at least certain thresholds (e.g., any exposure, ≥2 weeks ≥4 weeks ≥6 weeks ≥8 weeks etc.) will be displayed.  
Prior and concomitant medication:  
Prior medications are defined as treatments taken and stopped prior to first dose of study treatment. Any medication given at least once between the day of first dose of randomized study treatment and the date of the last study visit will be a concomitant medication, including those which were started pre -baseline and continued into the period where study treatment is 
administered.  
Prior and concomitant medications will be summarized in separate tables. Medications will be presented in alphabetical order, by [CONTACT_121974] (ATC) codes and grouped by [CONTACT_121975]. Tables will show the overall number and percentage of 
participants receiving at least one treatment of a particular ATC code and at least one treatment in a particular anatomical main group.  
The number and percentage of participants receiving systemic therapi[INVESTIGATOR_741666]. 
12.4 Analysis of the primary endpoint(s)/estimand(s)  
The analysis for the primary endpoint will be performed on SAF. 
12.4.1 Definition of primary endpoint(s)/estimand(s)  
All safety data, including laboratory measurements, vital signs, and AEs are considered primary 
endpoints. 
[COMPANY_001]  Confidential  Page 70 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 12.4.2 Statistical model, hypothesis, and method of analysis 
Only descriptive statistics will be provided, no inferential statistics will be conducted.  
Adverse events:  
Treatment emergent adverse events (TEAEs) will be summarized. Only primary paths within MedDRA will be considered for AE reporting. The definition for “treatment emergent” is as follows:  
• Events started on or after the first dose of study treatment or events present prior to the 
first dose of study treatment but increased in severity based on preferred term;  
• AEs observed four weeks after last study -drug administration will not be considered as 
treatment- emergent  
AEs will be summarized by [CONTACT_1601], for each treatment group, the number and percentage 
of participants having any AE, having an AE in each primary system organ class and having each individual AE (preferred term). Summaries will also be presented for AE s by [CONTACT_741692]. If a participant reported more than one AE with the same preferred term, the AE with the greatest severity will be presented. If a participant reported more than one AE within the same primary system organ  class, the participant will be counted 
only once with the greatest severity at the system organ class level, where applicable.  
SAEs will also be summarized.  
Separate summaries will be provided for deaths, SAEs, and other significant AEs leading to discontinuation. 
All AEs including non- treatment emergent AEs will be listed.  
Laboratory data:  
The summary of laboratory evaluations will be presented for two groups of laboratory tests 
(hematology and serum chemistry). Descriptive summary statistics for the change from baseline to each study visit will be presented. These descriptive summaries will be presented by [CONTACT_109058]. Change from baseline will only be summarized for participants with both baseline and post -baseline values. For each parameter, the maximum 
change from baseline will be analyzed analogously. Number and percentage of participants with notable abnormalities will be summarized.  
Vital signs:  
Analysis of the vital sign measurements using summary statistics for the change from baseline for each post -baseline visit will be performed. These descriptive summaries will be presented 
by [CONTACT_37297]. Change from baseline will only be  summarized for 
participants with both baseline and post -baseline values. Number and percentage of participants 
with notable abnormalities will also be summarized.  
12.4.[ADDRESS_1014067] occurred.  
[COMPANY_001]  Confidential  Page 71 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 12.4.4 Handling of missing values not related to intercurrent event  
Not applicable. 
12.4.5 Sensitivity analyses for primary endpoint/estimand 
Not applicable. 12.4.6 Supplementary analysis 
Not applicable. 12.4.7 Supportive analyses  
Not applicable. 
12.5 Analysis of secondary endpoints/estimands  
12.5.[ADDRESS_1014068], and 
visit/sampling time point.   
Descriptive summary statistics will be provided by [CONTACT_741693], including the frequency (n, %) of concentrations below the LLOQ. Summary statistics will include mean (arithmetic and geometric), SD, coefficient of variation (CV)  (arithmetic and 
geometric), median, minimum and maximum.  
Concentrations below LLOQ will be treated as zero in summary statistics.  
The following PK parameters will be determined: trough concentration (Ctrough), steady state (ss), and will be directly derived from the bioanalytical data (summary statistic tables; no non -
compartmental analysis will be performed).  
For each iscalimab concentration (or sample), an elapsed time since first (and last) dose of iscalimab will be calculated based on a Dose Reference ID (provided in the Blood Log). The time window for deriving the elapsed time will be defined in the SAP.  
Graphical presentation of the data will be provided. 
12.5.2 PK/PD relationships 
Data from this study may be used with pharmacokinetics/pharmacodynamics (PK/PD) models 
developed based on the core study CCFZ533B2201. This will be reported separately, if applicable. 
12.5.3 Immunogenicity  
All the results for immunogenicity data (anti -iscalimab antibodies) will be listed by [CONTACT_765]/time.  
If appropriate, summary statistics and shift tables will also be presented.  
[COMPANY_001]  Confidential  Page 72 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
   
  
 
 
 
 
12.7 Interim analyses  
Not applicable. 
12.8 Sample size calculation  
It is estimated that approximately 160 participants enrolled in the core study will complete the core study and be eligible for entry into the extension study. 
13 Ethical considerations and administrative procedures 
13.1 Regulatory and ethical compliance  
This clinical study was designed and shall be implemented, executed and reported in accordance with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local regulations (including European Directive 2001/20/EC, US CFR 21), and with the ethical 
principles laid down in the Declaration of Helsinki. 
13.2 Responsibilities of the investigator and IRB/IEC  
Before initiating a trial, the investigator/institution must obtain approval/favorable opi[INVESTIGATOR_30757]/Independent Ethics Committee (IRB/IEC) for the trial protocol, written informed consent form, consent form updates, participa nt recruitment procedures (e.g., 
advertisements) and any other written information to be provided to participants. Prior to study start, the investigator is required to sign a protocol signature [CONTACT_5389]/her agreement to conduct the study in accordance with these documents and all of the instructions and procedures found in this protocol and to give access to all relevant data and records to [COMPANY_001] monitor, auditors, [COMPANY_001] Quality Assurance representatives designated agents of [COMPANY_001], IRBs /IECs, and regulatory authorities as required. If an inspection of the clinical site is 
requested by a regulatory authority, the investigator must inform [COMPANY_001] immediately that this request has been made.  
13.[ADDRESS_1014069]. In addition, after study completion and finalization of the study report the results of this trial will be submitted for publication an d posted in a publicly accessible 
database of clinical trial results, such as the [COMPANY_001] clinical trial results website and all required Health Authority websites (e.g., Clinicaltrials.gov, EudraCT etc.). 

[COMPANY_001]  Confidential  Page 73 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 For details on the publication policy including authorship criteria, please refer to the publication policy training materials that were provided to you at the trial investigator meetings.  
13.[ADDRESS_1014070] Quality Management System (QMS) that includes all activities 
involved in quality assurance and quality control, to ensure compliance with written Standard Operating Procedures as well as applicable global/local GCP regulations and ICH Guidelines. 
Audits of investigator sites, vendors, and [COMPANY_001]  systems are performed by [CONTACT_6663], 
independent from those involved in conducting, monitoring or performing quality control of the 
clinical trial. The clinical audit process uses a knowledge/risk based approach.  
Audits are conducted to assess GCP compliance with global and local regulatory requirements, protocols and internal SOPs, and are performed according to written [COMPANY_001] processes. 
[ADDRESS_1014071] be considered a protocol amendment, and unless such an amendment is agreed upon by [CONTACT_30830]/IEC and Health Authorities, where required, it cannot be 
implemented.  
14.[ADDRESS_1014072] be approved by, health authorities where required, and the IRB/IEC prior to implementation.  
Only amendments that are required for participant safety may be implemented immediately provided the health authorities are subsequently notified by [CONTACT_6670]/IEC is notified.  
Notwithstanding the need for approval of formal protocol amendments, the investigator is expected to take any immediate action required for the safety of any participant  included in this 
study, even if this action represents a deviation from the protocol. In such cases, [COMPANY_001] should be notified of this action and the IRB/IEC at the study site should be informed according to local regulations.  
[COMPANY_001]  Confidential  Page 74 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 [ADDRESS_1014073]  
Asmussen K, Andersen V, Bendixen G, et al (1996) A new model for classification of disease manifestations in primary Sjögren's syndrome: evaluation in a retrospective long -term study. J 
Intern Med; 239:475-82. 
 
Fisher B, Zeher M, Ng W-F, et al (2017) The Novel Anti-CD40 Monoclonal Antibody CFZ533 Shows Beneficial Effects in Patients with Primary Sjögren’s Syndrome: A Phase IIa Double- Blind, Placebo- Controlled Randomized Trial [abstract]. Arthritis Rheumatol; 69 
(suppl 10). 
Gottenberg JE, Ravaud P, Puéchal X, et al (2014) Effects of hydroxychloroquine on 
symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial. JAMA; 312(3):249-58. 
Karnell JL, Rieder SA, Ettinger R, et al (2019) Targeting the CD40-CD40L pathway in 
autoimmune diseases: Humoral immunity and beyond. Adv. Drug Deliv. Rev. p. 92-103. 
 
Qin B, Wang J, Yang Z, et al (2015) Epi[INVESTIGATOR_410773]ögren's syndrome: a systematic review and meta-analysis. Ann Rheum Dis; 74:1983-9. 
Ramos -Casals M, Tzioufas AG, Font J (2005) Primary Sjögren's syndrome: new clinical and 
therapeutic concepts. Ann Rheum Dis; 64:347- 54. 
 
 
 
 
Shiboski CH, Shiboski SC, Seror R, et al (2017) 2016 American College of 
Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts. Arthritis Rheumatol; 69(1):35 -45. 
Stack RJ, Southworth S, Fisher BA, et al (2017) A qualitative exploration of physical, mental and ocular fatigue in patients with primary Sjögren's Syndrome. PLoS ONE; 12(10):e0187272. 
Theander E, Vasaitis L, Baecklund E, et al (2011) Lymphoid organisation in labial salivary 
gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren's syndrome. Ann Rheum Dis; 70:1363- 8. 

[COMPANY_001]  Confidential  Page 75 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
  
 
W
olff A, Joshi RK, Ekström J, et al (2017) A Guide to Medications Inducing Salivary Gland 
Dysfunction, Xerostomia, and Subjective Sialorrhea: A Systematic Review Sponsored by [CONTACT_741680]. Drugs R D; 17:1-28. 

[COMPANY_001]  Confidential  Page 76 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 16 Appendices  
16.1 Appendix 1: Clinically notable laboratory values and vital signs  
The following criteria will be used to define expanded limits and notable abnormalities of key 
laboratory tests.  
Table 16-[ADDRESS_1014074] units  SI units  
SGOT (AST)  ≥ 3 × ULN  ≥ 3 × ULN  
SGPT (ALT)  ≥ 3 × ULN  ≥ 3 × ULN  
Bilirubin  ≥ 3 × ULN  ≥ 3 × ULN  
Alkaline phosphatase  ≥ 5 × ULN  ≥ 5 × ULN  
GGT  ≥ 5 × ULN  ≥ 5 × ULN  
Renal function, metabolic and 
electrolyte variables      
Urea  ≥ 5 × ULN  ≥ 5 × ULN  
Creatinine  ≥ 3 mg/dL  ≥ 265 μmol/L  
Uric acid  M ≥ 12 mg/dL  M ≥ 714 μmol/L  
  F ≥ 9 mg/dL  F ≥535 μmol/L  
Glucose  < 45 mg/dL  < 2.5 mmol/L  
  > 250 mg/dL  > 13.9 mmol/L  
Cholesterol  ≥ 350 mg/dL  ≥ 9.1 mmol/L  
Triglycerides  ≥ 750 mg/dL  ≥ 8.5 mmol/L  
CK (MB)  None  None  
Potassium  ≤ 3.0 mEq/L  ≤ 3 mmol/L  
  ≥6.0 mEq/L  ≥6 mmol/L  
Calcium  ≤ 6 mg/dL  ≤ 1.5 mmol/L  
  ≥ 13 mg/dL  ≥ 3.2 mmol/L  
Magnesium  < 1.0 mg/dL  < 0.4 mmol/L  
  > 3.6 mg/dL  > 1.5 mmol/L  
Amylase  ≥ [ADDRESS_1014075]  ≥ [ADDRESS_1014076]  
Lipase  ≥ [ADDRESS_1014077]  ≥ [ADDRESS_1014078]  
Hematology variables      
Hemoglobin  < 7 g/dL  < 4.39 mmol/L  
Platelets (thrombocytes)  < 50 k/mm3 < 50 × 109/L 
  ≥ 700 k/mm3 ≥ 700 × 109/L 
Leukocytes (WBCs)  ≤ 2.0 k/mm3 ≤ 2.0 × 109/L 
  ≥ 16 k/mm3 ≥ 16 × 109/L 
Hematology variables:  
Differential      
[COMPANY_001]  Confidential  Page 77 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 Laboratory variable  
Liver function and related 
variables  Standard units  SI units  
Granulocytes (poly, 
neutrophils)   ≤ 1,000/mm3 ≤ 1 x 109/L 
Eosinophils  ≥ 12%   ≥ 12%  
Lymphocytes  ≤ 1,000/mm3 ≤ 1 × 109/L 
Vital sign variables  Notable criteria  
Systolic BP (mm/Hg)  Either an increase of ≥ 30 that results in ≥ 180 or > 200 (mm/Hg) 
OR a decrease of ≥30 that results in ≤ 90 or < 75 (mm/Hg)  
Diastolic BP (mm/Hg)  Either an increase of ≥ 20 that results in ≥ 105 or > 115(mm/Hg) 
OR a decrease of ≥20 that results in ≤ 50 or < 40 (mm/Hg)  
[COMPANY_001]  Confidential  Page 78 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 16.2 Appendix 2: Liver event and laboratory trigger definitions & 
follow -up requirements  
Table 16-2 Liver event and laboratory trigger definitions 
LIVER LABORATORY TRIGGERS  
LIVER EVENTS Definition/ threshold  
• [ADDRESS_1014079] < ALT / AST ≤ [ADDRESS_1014080]  
• 1.[ADDRESS_1014081] < TBL ≤ [ADDRESS_1014082]  
• ALT or AST > 5 × ULN  
• ALP > 2 × ULN (in the absence of known bone 
pathology)  
• TBL > 2 × ULN (in the absence of known Gilbert syndrome)
 
• ALT or AST > 3 × ULN and INR > 1.5  
• Potential Hy’s Law cases (defined as ALT or AST > 3 × ULN and TBL > 2 × ULN [mainly conjugated fraction] without notable increase in ALP to > 2 × ULN)
 
• Any clinical event of jaundice (or equivalent term)  
• ALT or AST > 3 × ULN accompanied by (general) 
malaise, fatigue, abdominal pain, nausea, or vomiting, 
or rash with eosinophilia  
• Any adverse event potentially indicative of a liver 
toxicity*  
*These events cover the following: Hepatic failure, fibrosis and cirrhosis, and other liver damage- 
related conditions; the non- infectious hepatitis; the benign, malignant and unspecified liver 
neoplasms TBL: total bilirubin; ULN: upper limit of normal  
Table 16-3 Follow up requirements for liver events and laboratory triggers  
Criteria  Actions required  Follow -up monitoring  
Potential Hy’s Law casea • Discontinue the study treatment immediately Hospi[INVESTIGATOR_18552], if clinically 
appropriate
 
• Establish causality  
• Record the AE and contributing factors (e.g., 
conmeds, med hx, lab) in 
the appropriate CRF  ALT, AST, TBL, Alb, PT/INR,  
ALP and GGT until resolutionc 
(frequency at investigator 
discretion)  
ALT or AST 
> 8 × ULN  • Discontinue the study 
treatment immediately  
• Hospi[INVESTIGATOR_6547]  
• Establish causality  
• Record the AE and 
contributing factors (e.g., ALT, AST, TBL, Alb, PT/INR,  
ALP and GGT until 
resolutionc  (frequency at 
investigator discretion)  
[COMPANY_001]  Confidential  Page 79 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 Criteria  Actions required  Follow -up monitoring  
conmeds, med hx, lab) in 
the appropriate CRF  
> 3 × ULN and INR > 1.5  • Discontinue the study  
• treatment immediately  
• Hospi[INVESTIGATOR_18552], if clinically appropriate
 
• Establish causality  
• Record the AE and contributing factors (e.g. 
conmeds, med hx, lab) in 
the appropriate CRF  ALT, AST, TBL, Alb, PT/INR,  
ALP and GGT until resolutionc 
(frequency at investigator discretion)  
> 5 to ≤ 8 × ULN  • Repeat LFT within 48 
hours  
• If elevation persists, 
continue follow -up 
monitoring  
• If elevation persists for more than 2 weeks, 
discontinue the study drug
 
• Establish causality  
• Record the AE and contributing factors (e.g., conmeds, med hx, lab) in 
the appropriate CRF  ALT, AST, TBL, Alb, PT/INR,  
ALP and GGT until resolutionc 
(frequency at investigator 
discretion)  
> 3 × ULN accompanied by [CONTACT_23805]
b • Discontinue the study 
treatment immediately  
• Hospi[INVESTIGATOR_6547]  
• Establish causality  
• Record the AE and contributing factors (e.g., 
conmeds, med hx, lab) in 
the appropriate CRF  ALT, AST, TBL, Alb, PT/INR,  
ALP and GGT until resolutionc 
(frequency at investigator 
discretion)  
> 3 to ≤ 5 × ULN (patient is asymptomatic)  • Repeat LFT within the next 
week  
• If elevation is confirmed, initiate close observation of 
the patient  Investigator discretion  
Monitor LFT within 1 to 4 
weeks  
ALP (isolated)  
> 2 × ULN (in the absence of 
known bone pathology)  • Repeat LFT within 48 hours
 
• If elevation persists, 
establish causality  
• Record the AE and 
contributing factors (e.g., Investigator discretion  
Monitor LFT within 1 to 4 
weeks or at next visit  
[COMPANY_001]  Confidential  Page 80 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 Criteria  Actions required  Follow -up monitoring  
conmeds, med hx, lab) in 
the appropriate CRF  
TBL (isolated)  
> 2 × ULN (in the absence of 
known Gilbert syndrome)  • Repeat LFT within 48 hours
 
• If elevation persists, 
discontinue the study drug 
immediately  
• Hospi[INVESTIGATOR_6547]  
• Establish causality  
• Record the AE and contributing factors (e.g., 
conmeds, med hx, lab) in 
the appropriate CRF  ALT, AST, TBL, Alb, PT/INR,  
ALP and GGT until resolutionc 
(frequency at investigator discretion)  
Test for hemolysis (e.g. 
reticulocytes, haptoglobin, unconjugated [indirect] 
bilirubin)  
> 1.5 to ≤ 2 × ULN (patient is asymptomatic)  • Repeat LFT within the next 
week  
• If elevation is confirmed, 
initiate close observation of 
the patient  Investigator discretion  
Monitor LFT within 1 to 4 weeks or at next visit  
Jaundice  • Discontinue the study 
treatment immediately  
• Hospi[INVESTIGATOR_18554]  
• Establish causality  
• Record the AE and 
contributing factors (e.g., 
conmeds, med hx, lab) in 
the appropriate CRF  ALT, AST, TBL, Alb, PT/INR,  
ALP and GGT until resolutionc 
(frequency at investigator 
discretion)  
Any AE potentially indicative of a liver toxicity*  • Consider study treatment interruption or 
discontinuation
 
• Hospi[INVESTIGATOR_157055]  
• Establish causality  
• Record the AE and 
contributing factors (e.g. 
conmeds, med hx, lab) in 
the appropriate CRF  Investigator discretion  
[COMPANY_001]  Confidential  Page 81 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 *These events cover the following: Hepatic failure, fibrosis and cirrhosis, and other liver damage- 
related conditions; the non- infectious hepatitis; the benign, malignant and unspecified liver neoplasms 
TBL: total bilirubin; ULN: upper limit of normal.  
aElevated ALT/AST > 3 × ULN and TBL > 2 × ULN but without notable increase in ALP to > 2 × 
ULN b(General) malaise, fatigue, abdominal pain, nausea, or vomiting, or rash with 
eosinophilia cResolution is defined as an outcome of one of the following: (1) return to baseline values, 
(2) stable values at three subsequent monitoring visits at least 2 weeks apart, (3) remain at elevated level after a maximum of 6 months, (4) liver transplantation, and (5) death. Based on investigator’s 
discretion investigation(s) for contributing factors for the liver event can include: Serology tests, imaging and pathology assessments, hepatologist’s consultancy; obtaining more detailed history of 
symptoms and prior or concurrent  diseases, history of concomitant drug use, exclusion of underlying 
liver disease.  
[COMPANY_001]  Confidential  Page 82 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 16.3 Appendix 3: Specific Renal Alert Criteria and Actions and Event 
Follow -up  
Table 16-4 Specific Renal Alert Criteria and Actions and Event Follow -up 
Serum Event  
Serum creatinine increase 25 – 49% 
compared to baseline  Confirm 25% increase after 24 -48h Follow up within 
2-5 days  
Acute Kidney Injury: Serum creatinine 
increase ≥ 50% compared to baseline  Follow up within 24- 48h if possible  
Consider study treatment interruption  
Consider patient hospi[INVESTIGATOR_059] /specialized treatment  
Urine Event  
New dipstick proteinuria ≥3+  
OR 
Protein -creatinine ratio ≥150 mg/g or ≥15 
mg/mmol  Consider causes and possible interventions  
• Assess serum albumin & serum total protein  
• Repeat assessment to confirm  
• Consider drug interruption or discontinuation  
unless other causes are diagnosed and  
corrected  
New dipstick hematuria ≥3+ on urine 
dipstick  Repeat assessment to confirm  
• Distinguish hemoglobinuria from hematuria  
• Urine sediment microscopy  
• Assess sCr  
• Exclude infection, trauma, bleeding from the 
distal urinary tract/bladder, menstruation  
• Consider bleeding disorder  
For all renal events:  
Document contributing factors in the CRF: co-medication, other co- morbid conditions, and 
additional diagnostic procedures performed  
Monitor patient regularly (frequency at investigator’s discretion) until either:  
Event resolution: sCr within 10% of baseline or protein -creatinine ratio within 50% of baseline, or  
Event stabilization: sCr level with ±10% variability over last 6 months or protein -creatinine ratio 
stabilization at a new level with ±50% variability over last 6 months.  
[COMPANY_001]  Confidential  Page 83 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 16.4 Appendix 4: Hepatitis B serology results and interpretation  
Not Applicable 
[COMPANY_001]  Confidential  Page 84 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 16.5 Appendix 5: Blood Logs  
Table 16-5 (A) - Blood Logs 
Period  Visit 
Name [CONTACT_741696]2 Immun
ology  Cryogl
obulins
3 PK blood collection4 Total 
(mL) 
        Size 
(mL) Size 
(mL) Size 
(mL) Size 
(mL) Size 
(mL) Size 
(mL) Sample  
Numbe
r Dose 
referen
ce ID    
Extensi
on-
Treatm
ent Wk 
60E15 421 60 - - 1.8 - - - - - 9.3 
  Wk 61  428 61 - - - - - - - - 0 
Wk 62  435 62 - - - - - - - - 0 
Wk 64  449 64 2 2.5 - - - - - - 4.5 
Wk 66  463 66 - - - - - - - - 0 
Wk 68  477 68 2 2.5 - 6 - - - - 10.5 
Wk 70  491 70 - - - - - - - - 0 
Wk 72  505 72 2 2.5 1.8 - 2 - - - 8.3 
Wk 74  519 74 - - - - - - - - 0 
Wk 76  533 76 2 2.5 - 6 - 3 101 1 13.5 
Wk 78  547 78 - - - - - - - - 0 
Wk 80  561 80 2 2.5 - - - - - - 4.5 
Wk 82  575 82 - - - - - - - - 0 
Wk 84  589 84 2 2.5 1.8 6 2 - - - 21.8 
Wk 86  603 86 - - - - - - - - 0 
Wk 88  617 88 2 2.5 - - - - - - 4.5 

[COMPANY_001]  Confidential  Page 85 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 Period  Visit 
Name [CONTACT_741697]2 Immun
ology  Cryogl
obulins
3 PK blood collection4 Total 
(mL) 
        Size (mL) Size (mL) Size (mL) Size (mL) Size (mL) Size (mL) Sample  
Numbe
r Dose 
referen
ce ID    
Wk 90  631 90 - - - - - - - - 0 
Wk 92  645 92 2 2.5 - 6 - 3 102 2 13.5 
Wk 94  659 94 - - - - - - - - 0 
Wk 96  673 96 2 2.5 1.8 - 2 - - - 8.3 
Wk 98  687 98 - - - - - - - - 0 
Wk 100  701 100 2 2.5 - 6 - - - - 10.5 
Wk 102  715 102 - - - - - - - - 0 
Wk 104  729 104 2 2.5 - - - - - - 4.5 
Wk 106  743 106 - - - - - - - - 0 
Wk 108/ 
TD6 [ADDRESS_1014083] -
Treatment 
Follow-
Up Wk 112  785 112 2 2.5 - 6 - - - - 10.5 
  Wk 120/ 
EOS7 [ADDRESS_1014084] antiphospholipid 
antibodies (lupus anticoagulant, anti -cardiolipin antibodies) and/or who are on pre-existing antithrombotic therapy/prophylaxis, as reflected in the exclusio n 
criteria of the TWINSS core study protocol. [ADDRESS_1014085] discontinued the study prematurely.  

[COMPANY_001]  Confidential  Page 86 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 Table 16-6 (B) - Blood Logs 
Period  Visit Name  [CONTACT_741698]1 Total (mL)  
      Size (mL)  Sample ID    
Extension -
Treatment  Wk 60E12 421 60 - - 0 
Wk 61  428 61 - - 0 
Wk 62  435 62 - - 0 
Wk 64  449 64 - - 0 
Wk 66  463 66 - - 0 
Wk 68  477 68 - - 0 
Wk 70  491 70 - - 0 
Wk 72  505 72 - - 0 
Wk 74  519 74 - - 0 
Wk 76  533 76 4 201 6 
Wk 78  547 78 - - 0 
Wk 80  561 80 - - 0 
Wk 82  575 82 - - 0 
Wk 84  589 84 - - 0 
Wk 86  603 86 - - 0 
Wk 88  617 88 - - 0 
Wk 90  631 90 - - 0 
Wk 92  645 92 4 202 6 
Wk 94  659 94 - - 0 
Wk 96  673 96 - - 0 
Wk 98  687 98 - - 0 
Wk 100  701 100 - - 0 
Wk 102  715 102 - - 0 

[COMPANY_001]  Confidential  Page 87 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 Period  Visit Name  [CONTACT_741698]1 Total (mL)  
      Size (mL)  Sample ID    
Wk 104  729 104 - - 0 
Wk 106  743 106 - - 0 
Wk 108/TD3 [ADDRESS_1014086] -
Treatment 
Follow -Up Wk 112  785 112 - - 0 
Wk 120/EOS4 [ADDRESS_1014087] discontinued the study prematurely.  

[COMPANY_001]  Confidential  Page 88 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 

[COMPANY_001]  Confidential  Page 89 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 

[COMPANY_001]  Confidential  Page 90 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 

[COMPANY_001]  Confidential  Page 91 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 

[COMPANY_001]  Confidential  Page 92 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 

[COMPANY_001]  Confidential  Page 93 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 

[COMPANY_001]  Confidential  Page 94 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 

[COMPANY_001]  Confidential  Page 95 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 

[COMPANY_001]  Confidential  Page 96 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 

[COMPANY_001]  Confidential  Page 97 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 16.10  Appendix 10: Satisfaction with self -injection using a prefilled 
syringe questionnaire 
Table 16-15  Satisfaction with self-injection using a prefilled syringe questionnaire 
 
[COMPANY_001]  Confidential  Page 98 of 98 
Amended Protocol Version v01 (Clean)   Protocol No. CCFZ533B2201E1  
 
 
 16.11  Appendix 11: Study design of core study CCFZ533B2201  
 
The core study will consist of a 6- week screening, 2 treatment periods of 24 weeks each, and a 
follow -up period of 12 weeks. In Periods 1 and 2, 13 treatment administration visits are planned, 
including weekly loading regimen (2 visits) at the start of eac h treatment period. One 
administration equals two s.c. injections. 
Primary analysis will occur at Week 24 including all participants but the analysis for Cohort 1 
and analysis for Cohort 2 may occur at different time points depending on patient recruitment and preparation timelines. While maintaining the blinding at Week 24, participants in the placebo arms D and F will be automatically switched to iscalimab (Arms D1 and F1, respectively) for treatment Period 2. All other participants (Arms A, B, C and E) will continue with their randomized iscalimab treatment from Period 1 into Period 2 (additional 24 weeks). The purpose of this second treatment period is to collect longer -term efficacy and safety data in 
a controlled, double -blinded fashion, while minimizing the number of participants who will 
continue to receive only pla cebo. 